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Zusammenfassung 
Die extrakapilläre proliferative Glomerulonephritis t durch eine glomeruläre Nekrose 
gekennzeichnet. Sterbende Zellen setzen intrazelluläre Proteine frei, die als damage-
associated molecular patterns agieren, um das angeborene Immunsystem zu aktivieren. Im 
Vorfeld haben wir bereits gezeigt, dass sterbende Tubuluszellen Histone freisetzen, welche 
Endothelzellen zerstören und den TLR2/4 Rezeptor aktivieren können. Dies führt zu einer 
tubulären-interstitiellen Entzündungsreaktion bei septischem oder post-ischämischem akuten 
Nierenversagen (ANV). Weiterhin haben andere Arbeitsgruppen bereits gezeigt, dass 
extrazelluläre Histone Organversagen bei akuter Lungenschädigung, Schlaganfall, Peritonitis 
und retinaler Dysfunktion verursachen können, und dass die Blockade von extrazellulären 
Histonen sich als ein vorteilhaftes Herangehen für das Fortschreiten der Erkrankung 
präsentiert. In dieser Doktorarbeit haben wir die pathogenen Effekte extrazellulärer Histone 
während nektorisierender Glomerulonephritis untersucht. Dies wurde unter Verwendung 
eines Tiermodells, welches auf einen nekrotisierenden Typ der schweren Glomerulonephritis 
basiert, erforscht. Nekrotisierende Glomerulonephritis wurde mittels einer einzigen 
intravenösen Injektion von 100μl Schaf GBM Antiserum induziert. Um den Einfluss der 
Histon-Neutralisierung zu untersuchen, haben wir einen Antikörper verwendet, der von dem 
BWA-3 Klon isoliert wurde. Dieser Antikörper besitzt die Fähigkeit, extrazelluläre Histone 
in-vitro und in-vivo zu neutralisieren. Nach 7 Tagen wurden die Nieren zur weiteren Analyse 
entnommen. 
Anti-GBM-behandelte Mäuse wiesen eine ansteigende Proteinurie (Albumin/Kreatinin 
Verhältnis), Plasma-Kreatinin und Harnstoff Werte auf. Dies war mit einer reduzierten 
Anzahl von Podozyten, ansteigender halbmondförmiger Glomeruli und infiltrierender 
Neutrophilen und Makrophagen in der Niere verbunden. Interessanterweise wurde die 
Proteinurie durch die Neutralisierung extrazellulärer Histone reduziert, was zu einem 
verminderten Podozytenschaden führte. Weiterhin war dies mit einer verbesserten renalen 
Funktionfähigkeit verbunden im Sinne von niedrigen Plasma-Kreatinin und Harnstoff 
Werten, und mit einer Abnahme der Neutrophilen und Makrophagen Infiltration und 
Aktivierung in der Niere. Die Blockade von Histonen reduzierten auch die renale mRNA 
Expression von TNF-α und Fibrinogen in den glomerulären Kapillaren signif kant, was mit 
geringeren Glomerulosklerose, Halbmonden und einer tubulären Atrophie assoziiert war. In-
vitro Studien zeigten, dass extrazelluläre Histone und NETs-verbundene Histone glomeruläre 
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Endothelzellen, Podozyten und parietale Epithelzellen in einem Dosis-abhängigen 
Zusammenhang zerstören können. Histon-neutralisierend  Mittel, wie Anti-Histon IgG, 
aktives Protein C oder Heparin unterdrückten diese zytotoxischen Effekte. Die Stimulation 
von BMDCs mit Histonen regulierte die Expression vo Aktivierungsmarkern, einschließlich 
MHC-II, CD48, CD80 und CD86 hoch sowie steigerte di Produktion von TNF-α und IL-6. 
Bisherig wurde von anderen sowie uns berichtet, dass es in Patienten mit ANCA-assoziierter 
Vaskulitis zu einer Überexpression des TLR2/4 Rezeptors im Vergleich zu gesunden 
Glomeruli kommt. Die Histon Toxizität bei Glomeruli ex-vivo war abhängig von der TLR2/4 
Rezeptor Achse, da das Ausschalten von TLR2/4 zur Abschwächung der Histon-induzierten 
renalen thrombotischen Angiopathie und glomerulären N krose in Mäusen führte. Anti-GBM 
Glomerulonephritis involviert NET Formation und vaskuläre Nekrose, während die Blockade 
von NETs durch PAD Inhibierung oder präventive Anti-Histon IgG Injektion signifikant alle 
Parameter der Glomerulonephritis reduzierten, einschließlich vaskuläre Nekrose, 
Podozytenverlust, Albuminurie, Produktion von Zytokinen, Rekrutierung und Aktivierung 
von glomerulären Leukozyten, und glomerulärer Halbmondformation. Um Histone als 
therapeutisches Ziel zu evaluieren, wurden Mäuse mit bereits etablierter Glomerulonephritis 
mit drei verschiedenen Histon-neutralisierenden Mitteln, wie Anti-Histon IgG, aktiviertes 
Protein C und Heparin, behandelt. Interessanterweise, weisen alle drei Mittel eine 
gleichwertige Effektivität auf, was zur reduzierten Glomerulonephritis beitrug, wohingegen 
die Kombinationstherapie keinen additiven Effekt hatte. 
Zusammenfassend zeigen die Ergebnisse dieser Arbeit, dass NET-verbundene Histone, 
welche während der Glomerulonephritis freigesetzt werden, zytotoxische und 
immunostimulierende Effekte hervorrufen, und dass die Neutralisierung extrazellulärer 
Histone als potentielle Therapie bei bestehender Glomerulonephritis eingesetzt werden 
könnte.  
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Summary 
Crescentic glomerulonephritis is characterized by glomerular necrosis. Dying cells release 
intracellular proteins that act as danger-associated molecular patterns to activate the innate 
immune system. Previously, we have demonstrated that dying tubular cells release histones, 
which can kill endothelial cells and activate the toll-like receptor 2/4 (TLR2/4). This drives 
tubulointerstitial inflammation in septic or post-ichemic acute kidney injury (AKI). 
Furthermore, other groups have also reported that extracellular histones cause organ damage 
during acute lung injury, stroke, peritonitis and retinal dysfunction, and that blocking 
extracellular histones represents a beneficial approach during the disease progression. In this 
thesis, we investigated whether extracellular histones can elicit similar pathogenic effects 
during necrotizing glomerulonephritis. To do so, weused an animal model based on the 
necrotizing type of severe glomerulonephritis. Necroti  glomerulonephritis was induced in 
mice by a single intravenous injection of 100µl sheep anti-GBM antiserum. The impact of 
histone neutralization was studied by using an antibody isolated from the BWA-3 clone, 
which had the capacity to neutralize released extracellular histones in-vivo and in-vitro. After 
7 days, mice were sacrificed and kidneys were colleted for further data analysis. Proteinuria 
was assessed in spot urine samples. 
Anti-GBM treated mice showed increased proteinuria (albumin/creatinine ratio), plasma 
creatinine and BUN levels. This was associated with a reduced number of podocytes, 
increased crescentic glomeruli and the infiltration of neutrophils and macrophages into the 
kidney. Interestingly, neutralization of extracellular histones significantly reduced proteinuria 
leading to less podocyte damage. This was linked to an improved renal function defined by 
lower plasma creatinine and BUN levels, and with a decrease in neutrophil and macrophage 
infiltration and activation in kidney. Histone blockade also significantly reduced renal mRNA 
expression of TNF-α and fibrinogen in the glomerular capillaries, which was associated with 
less glomerulosclerosis, crescents and tubular atrophy. In-vitro studies demonstrated that 
extracellular histones and NETs-related histones kill glomerular endothelial cells, podocytes 
and parietal epithelial cells in a dose-dependent manner. Histone-neutralizing agents such as 
anti-histone IgG, activated protein C or heparin prevented this cytotoxic effect. Stimulation of 
BMDCs with histones upregulated the expression of the activation marker including MHC-II, 
CD48, CD80 and CD86 significantly as well as increased the production of TNF-α and IL-6. 
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It has been previously reported by others including us that in biopsies from patients with 
ANCA-associated vasculitis showed an over-expression of the TLR2/4 receptor compared to 
the healthy glomeruli. Histone toxicity on glomeruli ex-vivo was also dependent on the 
TLR2/4 receptor axis given that the lack of TLR2/4 attenuated histone-induced renal 
thrombotic microangiopathy and glomerular necrosis in mice. Anti-GBM glomerulonephritis 
involved NET formation and vascular necrosis, while b ocking NET formation via PAD 
inhibitor or pre-emptive anti-histone IgG injection significantly reduced all parameters of 
glomerulonephritis including vascular necrosis, podocyte loss, albuminuria, cytokine 
induction, recruitment and activation of glomerular eukocytes, and glomerular crescent 
formation. Finally, to evaluate histones as a therap utic target, mice with established 
glomerulonephritis were treated with three different histone-neutralizing agents such as anti-
histone IgG, recombinant activated protein C and/or heparin. Interestingly, all agents were 
equally effective in abrogating severe glomerulonephritis, while combination therapy had no 
additive effect. 
In summary, the results of this thesis indicate that NET-related histones released during 
glomerulonephritis elicit cytotoxic and immunostimulatory effects and that neutralizing 
extracellular histones, therefore, represents a potential therapeutic approach when applied 
during already established glomerulonephritis. 
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1. Introduction 
1.1. Sterile inflammation 
Inflammation is vital for host defence against invasi e pathogens1. In response to an 
infection, a cascade of signals leads to the recruitment of inflammatory cells by activating 
pattern recognition receptors (PRRs), particularly in innate immune cells such as neutrophils 
and macrophages. These cells, in turn, phagocytose infectious agents and produce additional 
cytokines and chemokines that lead to the activation of lymphocytes and adaptive immune 
responses. It is now evident that PRRs also recognize non-infectious material that can cause 
tissue damage and endogenous molecules that are released during cellular injury and death. 
These endogenous molecules have been termed damage-associated molecular patterns 
(DAMPs) (Table 1), as these host-derived non-microbial stimuli are released following tissue 
injury or cell death and have similar functions as pathogen-associated molecular patterns 
(PAMPs) in terms of their ability to activate pro-inflammatory pathways2. 
In 1994, Polly Matzinger proposed that the immune system is more concerned with ‘danger’ 
or ‘damage’ than with the distinction between self and non-self3. The model starts with the 
idea that the immune system defines danger as anything t at causes tissue stress or 
destruction4,5. In this model, antigen-presenting cells are activted by DAMPs from stressed 
and/or damaged tissues. Matzinger’s ‘danger model’ suggests why potent immune responses 
are initially elicited in the setting of sterile inflammation5. 
DAMPs are cell-derived molecules that can initiate nd perpetuate immunity in response to 
trauma, ischemia, cancer, and other settings of tissue damage in the absence of overt 
pathogenic infection. DAMPs are localized within the nucleus and cytoplasm (HMGB1), 
cytoplasm alone (S100 proteins), exosomes [heat shock proteins (HSP)], the extracellular  
matrix (hyaluronic acid), and in plasma components such as complement (C3a, C4a and 
C5a). Examples of non-protein DAMPs include ATP, uric acid, heparin sulfate, RNA, and 
DNA. DAMPs can also be mimicked by release of intracellular mitochondria consisting of 
formyl peptides and mitochondrial DNA (with CpG DNA repeats) to activate human 
polymorphonuclear neutrophils through activation of TLR96. 
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Table: 1. List of the sterile inflammatory signals, its receptors and associated pathology2. (The 
table is adapted from Chen et al. Nature Reviews Immunology, 2010) 
Sterile inflammatory 
signal 
Putative sensor Associated pathology 
Endogenous  
  
HMGB1 
TLR2, TLR4, TLR9, RAGE 
and CD24 
Cellular injury and necrosis 
HSPs 
TLR2, TLR4, CD91, CD24, 
CD14 and CD40 
Cellular injury and necrosis 
S100 proteins RAGE Cellular injury and necrosis 
SAP130 CLEC4E Cellular injury and necrosis 
RNA TLR3 Cellular injury and necrosis 
DNA TLR9 and AIM2 Cellular injury and necrosis 
Uric acid and MSU 
crystals 
NLRP3 Gout 
ATP NLRP3 Cellular injury and necrosis 
Hyaluronan TLR2, TLR4 and CD44 Cellular injury and ecrosis 
Biglycan TLR2 and TLR4 Cellular injury and necrosis 
Versican TLR2 Cellular injury and necrosis 
Heparan sulphate TLR4 Cellular injury and necrosis 
Formyl peptides 
(mitochondrial) 
FPR1 Cellular injury and necrosis 
DNA (mitochondrial) TLR9 Cellular injury and necrosis 
CPPD crystals NLRP3 Pseudogout 
β-amyloid NLRP3, CD36 and RAGE Alzheimer's disease 
Cholesterol crystals NLRP3 and CD36 Atherosclerosis 
IL-1α IL-1R Cellular injury and necrosis 
IL-33 ST2 Cellular injury and necrosis 
Exogenous  
  
Silica NLRP3 
Silicosis and pulmonary 
interstitial fibrosis 
Asbestos NLRP3 
Asbestosis and pulmonary 
interstitial fibrosis 
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1.2.  Mechanism of sterile inflammation 
Despite the growing list of sterile immune stimuli, the mechanisms by which these stimuli 
trigger an inflammatory response are still not fully understood. Even though endogenously 
generated DAMPs are structurally heterogeneous, the outcome of inflammatory responses to 
these stimuli is generally uniform. The release of DAMPs from dying cells is illustrated in the 
Figure 1. 
 
  
Figure: 1. During homeostasis most commonly cells in the body undergo apoptosis and they are 
removed by phagocytosis without any injury to the targeted organ and replaced by new cells of the 
same phenotype. When there is irreversible stress or toxin exposure, the cells undergo a pathogenic 
form of cell death such as necrosis that results in the release of cellular contents called damage-
associated molecular patterns (listed in table 1). These damage-associated molecular patterns will be 
recognized by pattern recognition receptors on immune cells to activate the release of pro-
inflammatory cytokines and chemokines. The released DAMPs can also kill cells within the targeted 
organs to cause severe inflammatory responses leading to organ failure.   
Apoptosis
Necrosis and 
release of DAMPS
Activation of Ag-presenting cells
Inflammation
Normal cell
Necrosis of epithelial
cells and DAMP release
Removal by phagocytosis
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Moreover, inflammatory responses during infection are very similar to responses induced by 
sterile stimuli including the recruitment of neutrophils and macrophages, the production of 
inflammatory cytokines and chemokines, and the induction of T cell-mediated adaptive 
immune responses7. This suggests that both infectious and sterile stimuli may function 
through common receptors and pathways. Based on the curr nt understanding, there are three 
proposed mechanisms by which sterile endogenous stimuli trigger inflammation: (1) the 
activation of PRRs by mechanisms similar to those used by microorganisms and PAMPs, (2) 
the release of intracellular cytokines and chemokines, such as interleukin (IL)-1α, that 
activates common pathways downstream of PRRs, and (3) the direct activation of receptors 
that are not typically associated with microbial recognition2. 
 
1.3. DAMPs and kidney diseases 
Currently, most of the experimental data provide information about DAMPs playing an 
important role in the progression of kidney diseases. Indirect evidence from animal model, 
where mice lacking specific DAMP receptors showed protection of kidney diseases that will 
be further discussed within this section.   
1.3.1. Acute kidney injury 
Tubular necrosis 
Compared to all other forms of kidney diseases, acute kidney injury (AKI) always linked to 
cells with abundant amounts of necrosis, which leads to inflammatory DAMPs release and 
activation of innate and adaptive immunity triggering inflammation with aggravated AKI. 
The injury is mainly caused due to the activation of DAMP receptors like toll-like receptors 
(TLRs) and receptor for advanced glycation end-products (RAGE).8 For example high-
mobility group protein B1 (HMGB1), heat shock proteins (HSPs) and histones are well-
known DAMPs that are released during tubular necrosis a  in the case of septic, ischemic, or 
toxic forms of tubular necrosis. This further drives sterile inflammatory and immune 
pathologies that regulate organ failure9-15. Reports have shown that death during sepsis is 
mainly due to the release of DAMPs like HMGB1, histones, decorin, or biglycan10,13,16,17. 
The lethality is based on DAMP-mediated endothelial dysfunction, which involves TLR2/4 
receptors leading to increased vascular permeability and hypovolemic shock18. HSP and gp96 
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regulate the TLR2-mediated ERK pathway and inflammation during hypoxia or ischemic 
kidney conditions19. Geldanamycin, an inhibitor of Hsp90 and gp96, protects mice from 
IRI20. Non-pathogenic and non-cellular DAMPs like high con entrations of uric acid 
accumulate during the ischemic kidney and activate the immune system leading to the severe 
inflammation in the kidney21. 
Glomerulonephritis 
Glomerular cells undergoing necrosis also release DAMPs during the necrotizing type of 
glomerulonephritis leading to AKI and glomerulonephritis (GN)22. Serum and tissue 
expression levels of HMGB1 are reported during experim ntal models of glomerulonephritis. 
Like in tubular necrosis, TLR2/4 deficiency reduces the complications of 
glomerulonephritis23,24. Histones on the other hand are released from NETting neutrophils in 
necrotizing GN25.  
1.3.2. Chronic kidney injury 
Diabetic nephropathy 
Inflammatory responses mediated by activation of TLR2, TLR4 and the NLRP3 
inflammasome play key roles in the progression of diabetic nephropathy (DN)26,27. Reactive 
oxygen species or extracellular ATP can activate the NLRP3 inflammasome during diabetic 
conditions26,28. The ATP receptor P2X4 is over expressed on renal TECs from patients with 
type 2 DN conditions; this is mainly due to the hyperglycaemic complications of diabetes, 
which correlates with the release of IL-1 cytokines26. Biglycan and decorin are overexpressed 
in diabetic kidneys and may trigger inflammation by activating the TLR2/TLR4 receptors and 
the NLRP3 inflammasome29-31. An increase in renal biglycan promotes LDL cholesterol, 
which leads to the infiltration of macrophages and upholds kidney injury30.  
There is expansive literature on the involvement of AGE and RAGE in podocytes, diabetes, 
and DN 32-37. S100, a pro-inflammatory RAGE ligand, is involved in a novel pathway for 
leukocyte recruitment during inflammatory disorders and diabetic conditions in mice38. 
RAGE and S100 are over-expressed in the podocytes of db/db mice, which contributes to 
both renal pathology and inflammation with increased infiltration of mononuclear phagocytes 
to the glomeruli. These effects can be blocked withthe anti-RAGE antibody39. 
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Lupus nephritis 
Lupus nephritis is an inflammatory kidney disease caused by the autoimmune disorder 
systemic lupus erythematosus (SLE), which involves immune activation by nuclear DAMPs 
that share autoantigen and adjuvant qualities40. The disease is mainly characterized by 
hyperproliferation of autoreactive lymphocytes, which enhance the autoantigen presentation. 
The effect is due to the activation of TLR7 and TLR9 receptor activating DAMPs like 
Ribonucleoproteins and hypomethylated dsDNA, respectively41. In addition, these TLR7- and 
TLR9-specific DAMPs trigger plasmacytoid dendritic cells to release IFN-α, which initiates 
antiviral gene transcription accounting for many of the unspecific (viral infection-like) 
symptoms of lupus42 and IFN-related glomerular pathology43. TLR7 and TLR9 activation 
also leads to the generation and maturation of M1 type  macrophages, which further activates 
the pathogenicity of lupus nephritis44-46. Biglycans has been shown to trigger lupus nephritis 
by activating TLR2 and TLR4 leading to the over expr ssion of chemokines including CCL2, 
CCL3 and CCL5, and aggravated murine lupus nephritis47. 
Pathogenic effects of HMGB1 have been linked to a variety of pro-inflammatory and 
autoimmune diseases including SLE. Reports have shown that SLE patients have high levels 
of circulating HMGB1, which is also the case in mouse models of SLE48-50. The pathogenic 
effect of HMGB1 is mainly due to the antibody-induced immune complex deposition, a type 
of kidney damage in SLE51. In lupus-prone MRL-Fas(lpr) mice, p38 MAPK activaon 
induced infiltration and maturation of dendritic cells (DCs) and secretion of HMGB1 from 
DCs has been implicated in autoimmune kidney diseases52. 
 
1.4. Extracellular histones 
Histones are important structural elements of the nuclear chromatin and can regulate gene 
transcription. In contrast, outside the cell histones elicit toxic and immunostimulatory effects. 
This becomes obvious when infectious organisms trigge  granulocytes (and macrophages) to 
undergo a particular type of programmed cell death that catapults the chromatin outside the 
cell to cover and kill pathogens, e.g. NETosis. Pro-inflammatory cytokines also have the 
ability to induce the process of NETosis, which contributes to sterile forms of inflammation 
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and tissue injury. As illustrated in figure 2, whic describes in more detail how the histone 
component of extracellular chromatin mediates injury and triggers innate immunity including 
activation of TLRs or inflammasomes (Figure 2). Furthe more, we discuss how to target 
extracellular histones to improve disease outcomes using different histone blocking agents. 
 
 
 
 
Figure: 2. How histones trigger tissue injury and inflammation. Various forms of cell necrosis release 
chromatin into the extracellular space. Histone-specific effects and their consequences for the disease. 
A number of molecules inhibit histone effects such as, Activated protein C degrades histones in the 
extracellular space. Other elements can also neutralize the specific effects without degrading the 
histone structure like heparin, albumin and neutralizing histone antibody 53. 
 
 
 
Introduction                                                                                                                            8 
1.5. Structure and functions of histones  
The eukaryotic cell nucleus maintains DNA and histones in a highly organized chromatin 
format, which is conserved across species. There ar five classes of histones: H2A, H2B, H3 
and H4 that are known as ‘core histones’, while H1 represent ‘linker histones’54. Structurally, 
all core histones share a common structural motif cnsisting of a long central helix flanked by 
a helix-strand-helix motif on each end. This “histone fold” exhibits high hydrophobic 
interactions to form dimers and tetramers within the core histones (Figure 3). The 
organizational unit of chromatin, the nucleosome consists of one H3/H4 tetramer and two 
H2A/H2B dimers also called the “histone octamer”, coiling 147bp of DNA in approximately 
two parallel strands, while H1 binds to non-nucleosomal DNA to form higher-order 
chromatin structures. These octamers are stabilized by C-terminal helices of core histones. 
The basic nature of the histone proteins neutralizes th  acidic residues of the DNA. Each 
histone has its N-terminal tail rich in lysine and arginine residues that extend out from the 
core structure. These amino-terminal sites are flexibl  and undergo numerous post-
translational modifications such as acetylation, phosphorylation, methylation, ubiquitination, 
sumoylation, and ADP ribosylation, which play a key role in gene replication and 
regulation55.  
Histone methylation, phosphorylation and acetylation serve as markers for the transcriptional 
state of genes in several diseases and distinct post-tran lational modification patterns are 
linked to certain inflammatory diseases56. While histones are completely inert within the 
nucleus, they elicit pathogenic effects outside the cell. Histones are released from dying cells 
and contribute to antimicrobial defence responses during infection10,57.  
However, extracellular histones are a double-edged sword because they also damage host 
tissue and may cause death. But when and how histones access the extracellular space? This 
is discussed in the next section. 
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Figure: 3. Structure of histone octamer with the core histones H2A, H2B, H3 and H4 and the linker 
histone H1. Coiled dsDNA surrounds the histones, which forms the complete nucleosome. 
 
1.6. Mode of histone release into the extracellular space 
Releasing chromatin requires rupture of the nuclear and outer cell membrane, e.g. during cell 
death58. Apoptosis avoids membrane disintegration, therefore apoptosis was considered a 
‘silent death’ that rather contributes to cell turnover and lymphocyte selection during 
homeostasis59. However, histones have been reported to accumulate in and leak also from 
membrane blebs of apoptotic cells60. In contrast, disruption of the outer plasma membrane, as 
it occurs during necrotic cell death, massively releases intracellular components that have the 
capacity to activate innate immunity, referred to as danger/damage-associated molecular 
patterns (DAMPs) or alarmins. Later the histones reach the extracellular space and act as 
DAMPs to activate innate immunity61. The forms of necrosis that exist in the biological 
system will be described in more detail within this section. 
1.6.1. Necrosis 
Necrosis is an active form of cell death and occurs predominantly due to the irreversible 
stress on tissue cells, e.g. hypoxia, radiation, changes in pH or toxic chemicals. Necrosis 
leads to the complete destruction of the cell integri y resulting in the release of DAMPs 
followed by the loss of function. 
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1.6.2. Passive necrosis 
Mechanical trauma or charge- or detergent-related toxici y passively disrupt the plasma 
membrane59. In view of recent data on regulated forms of necrosis, it is fair to speculate that 
passive necrosis is a rather rare event in clinical medicine62. Regulated necrosis is defined as 
a genetically controlled cell death process that eventually results in cellular leakage, and it is 
morphologically characterized by cytoplasmic granultion, as well as organelle and/or 
cellular swelling ('oncosis')62. The different forms of regulated necrosis are as follows. 
NETosis/ETosis 
NETosis/ETosis is a regulated form of necrosis that is restricted to immune cells like 
neutrophils (NETosis) and other granulocytes or macrophages (ETosis)62. Pro-inflammatory 
cytokines such as IL-8 or TNF-α can activate neutrophils to undergo regulated burst, a 
process that takes up to 6 hours and spreads all chromatin to the outside of the cells in a net-
like structure NETs (neutrophil extracellular traps)63. Akt- and NOX2-dependent reactive 
oxygen species facilitate and trigger NETosis 64 as well as the activation of TLR2, TLR4, 
complement, and platelet 65,66. NETosis results in the release of histones from cells that are 
present at sites of infection as well as during sterile inflammation25,62. 
Pyroptosis 
Pyroptosis is mechanistically distinct from other fo ms of cell death. Caspase 1 dependence is 
a defined feature of pyroptosis, and caspase 1 is the enzyme that mediates this process of cell 
death67,68. However, caspase 1 is not involved in apoptotic cell death that was confirmed in 
caspase 1-deficient mice, which had no defects in apoptosis and developed normally. 
Pyroptosis also involves the involvement of a Caspase 11-dependent form of regulated 
necrosis downstream of inflammasome activation69. Until now, pyroptosis has mainly been 
described in infected macrophages and as being responsible for the loss of T cells in patients 
with AIDS70,71. Its role in tissue necrosis remains to be explored. The apoptotic caspases 
including caspase 3, caspase 6 and caspase 8 are not involved in pyroptosis72,73, and 
substrates of apoptotic caspases including poly (ADP-ribose) polymerase and inhibitor of 
caspase-activated DNase (ICAD) do not undergo proteolysis during pyroptosis67,68,74,75. 
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Necroptosis 
Necroptosis is a mechanism of necrotic cell death induced by external stimuli leading to the 
engagement of death domain receptors (DRs) with their respective ligands such as TNF-α, 
Fas ligand (FasL) and TRAIL. This happens under conditions when apoptotic cell death 
execution is prevented, e.g. by caspase inhibitors. Although it occurs under regulated 
conditions, necroptotic cell death is characterized by the same morphological features as 
unregulated necrotic death. RIP1 kinase activity is a key step in the necroptosis pathway, 
followed by the activation of RIP3 kinase and phosphorylation of MLKL, which form a 
complex known as the necroptosome. Necroptosis may be a central mode of regulated 
necrosis under inflammatory conditions76-78. 
Cyclophilin D-mediated regulated necrosis 
Cyclophilin D-mediated regulated necrosis disrupts the mitochondrial transmembrane 
potential, which opens mitochondrial membranes and translocates NAD+ to the cytosol79,80. 
Mitochondrial dysfunction is the first step in ischemia-associated forms of regulated 
necrosis81. 
Ferroptosis 
The oncogenic RAS-selective lethal small molecule erastin triggers a unique iron-dependent 
form of non-apoptotic cell death, called ferroptosis. Ferroptosis is dependent on intracellular 
iron, but not other metals, and is morphologically, biochemically and genetically distinct 
from apoptosis, necrosis and autophagy82. Oxidative stress is also a trigger for ferroptosis, a 
recently described iron-dependent form of regulated n crosis. Under normal conditions, 
glutathione peroxidase 4 levels inhibit ferroptosis, and its depletion during oxidative stress 
can set off the cell death event83. 
Podoptosis 
Podoptosis is another regulated cell death pathway occurs mainly in non-dividing cells like 
podocytes, it is mainly due to the p53-overactivation-dependent cell death, thus, referred as 
podoptosis. Podoptosis is associated with cytoplasmic vacuolization, endoplasmic reticulum 
stress, and dysregulated autophagy leading to the release of DAMPs84. 
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1.7. Pathogenic effects of extracellular histones 
Some of the reported pathogenic effects of released extracellular histone are illustrated in the 
Figure 4 and will be further discussed in this section. 
1.7.1. Bactericidal effects  
In late 1950s, James G. Hirsch first reported that e arginine-rich fraction of calf thymus 
histone (histone B) exerts bactericidal activity on various coliform bacilli and micrococci 
under certain conditions in-vitro57. Concentrations less than 1µg/ml histones kill susceptible 
microbes without detectable morphological alteration or lysis. This was later confirmed by 
other groups63,85-87. Microorganisms which are highly susceptible to histone toxicity are 
Escherichia, Salmonella, Shigella, Pseudomonas, Klebsiella, and Micrococcus pyogenes var. 
albus. Less susceptible or completely resistant are Proteus, Serratia, Micrococcus pyogenes 
var. aureus, and various types of hemolytic streptococci. but the mode of this bactericidal 
effect remained unknown57. It has been suggested that their basic charge and their capacity to 
bind strongly to anionic moieties of the bacterial cell wall damage the osmotic barrier57.  
 
Figure: 4. Release and activity of histones in response to stres 88 and its pathogenic effects on 
different organs 
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1.7.2. Cellular toxicity 
Xu et al. reported for the first time that the unspecific cytotoxic effects of extracellular 
histones on the host leading to lethal effects during sepsis10. Histone release in sepsis or 
major trauma primarily affects endothelial cells that can cause fatal organ dysfunction10,89. 
Intravenous injection of recombinant histones kills healthy mice within a few minutes due to 
severe endothelial damage in the microvasculature of the lungs10. Similarly, injection of 
histones into the renal artery causes microvascular inju y and ischemic renal necrosis9. 
Histone-induced endothelial permeability and death is a non-regulated form of necrosis that is 
mediated through a charge-dependent mechanism resulting in disruption of junctional protein 
expression and cell death90. In fact, the anionic molecule polysialic acid can abrogate NET-
mediated alveolar epithelial injury91. However, despite having a similar charge only histone 
H1, but not H2A, H2B, H3, and H4 is neurotoxic92, which suggests cell type-specific effects. 
For example, histone H1 kills neurons but not astrocytes or microglia92. In addition, it is 
currently not known whether histones trigger any of the recently described forms of regulated 
necrosis62. 
1.7.3. TLR activation 
Xu et al. has recently shown that histones specifically induce TLR2- and TLR4-mediated 
reporter gene expression in a cell line overexpressing different classes of TLRs10. Histones 
can also bind and activate the TLR2 and TLR4 receptors leading to the activation of the 
Myd88 pathway, which further results in an inflammatory response by activating NF-κB and 
mitogen activated protein kinase target gene expression9,93,94. Furthermore, histone-induced 
tissue injury is partially dependent on TLR2/49,94 that is to other cell-derived extracellular 
DAMPs, which activate predominantly TLR2/4 receptors and show immunogenic actions95. 
Whereas, Huang et al. reported that extracellular histones activate TLR9 and contribute to 
postischemic liver failure in a TLR9-dependent manner96. In this study, anti-histone IgG had 
almost a comparable protective effect on organ functio  as TLR9 gene deletion, yet in gene-
deleted mice. These antibodies did not show any additional effect96. However, in our in-vitro 
studies, Allam et al. could not confirm the data from Huang and colleagues that TLR9 acts as 
a receptor for histones9, possibly this maybe because of residual TLR9-agonistic DNA 
complexes within histones, which normally occur in-vivo. 
Introduction                                                                                                                            14 
1.7.4. NLRP3 inflammasome activation 
The Nod-like receptor (NLR) family is characterized by the presence of a central nucleotide-
binding and oligomerization (NACHT) domain, which is commonly flanked by C-terminal 
leucine-rich repeats (LRRs) and N-terminal caspase recruitment (CARD) or pyrin (PYD) 
domains. LRRs are believed to function in ligand sensing and autoregulation, whereas CARD 
and PYD domains mediate homotypic protein-protein interactions for downstream 
signaling97. The NACHT domain, which is the only domain common t  all NLR family 
members, enables activation of the signaling complex via ATP-dependent oligomerization. 
The NLRP3 inflammasome is a cytosolic platform, activated upon cellular infection or stress 
that integrates various danger signals into the caspase-1-dependent maturation of pro-
inflammatory cytokines such as IL-1β to initiate innate immune defences97. 
Allam R et al. has recently reported that cytosolic uptake of necrotic cell-derived histones 
trigger mechanisms of sterile inflammation, which involve NLRP3 inflammasome activation 
and IL-1β secretion via oxidative stress98. This may be due to the existence of histones in its 
particle nature, as it is observed by many crystals and microparticles that are capable of 
activating NLRP3 inflammasome complexes99,100. Intraperitoneal injection of histones into 
Nlrp3 gene deficient mice significantly reduces IL-1β production and recruitment of 
neutrophils causing attenuated histone-induced peritonitis98. 
1.7.5. Platelet activation 
Fuchs et al. has published for the first time an interactions of extracellular histones with 
platelets. Histones that have bound to platelets induced calcium influx and recruited plasma 
adhesion proteins such as fibrinogen to induce platelet aggregation93,101-103. Hereby, 
fibrinogen cross-linked histone-bearing platelets and triggered micro-aggregation. Whereas 
the interaction of fibrinogen with αIIbβ3 integrins were not required for this process, but were 
necessary for the formation of large platelet aggreat s. Intravenous administration of 
histones caused the profound thrombocytopenia within m nutes after administration in-
vivo101. Mice lacking platelets or αIIbβ3 integrins were protected from histone-induced death 
but not from histone-induced tissue damage. In contrast, heparin and albumin prevented 
histone interactions with platelets and protected mice from histone-induced 
thrombocytopenia, tissue damage and death101,103. Extracellular histones also induced platelet 
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aggregation and clotting that was dependent on the presence of TLR2/4 and downstream 
signaling via ERK, p38, AKT and NF-κB93,104. 
1.7.6. Protecting DNA degradation 
DNA in chromatin is arranged in form of arrays of nucleosomes, highly conserved 
nucleoprotein complex. The X-ray crystal structure of the nucleosome core particle of 
chromatin shows in atomic detail how the histone protein octamer is assembled and how 146 
base pairs of DNA are organized into a superhelix around it105. Von Hahn et al. reported that 
histones stabilize the extracellular DNA against the t ermal degradation i -vitro106. Histones 
in form of nucleosomes protect the DNA from further d gradation by nucleases, which leads 
to the stabilization of DNA within the system and contributes to autoimmune complications. 
For example, in SLE, where genetic variants often compromise phagocytic dead cell and 
chromatin clearance and the persistence of extracellular chromatin fosters immunization 
against DNA and histones107,108. SLE patients who cannot dismantle NETs might be a useful 
indicator of the renal involvement108. To be protected from lupus, autoantigens such as 
dsDNA from degradation inside injured organs will need to remain accessible to circulating 
anti-dsDNA antibodies, a process that is involved in the pathogenesis of lupus nephritis40,109. 
However, this mechanism can explain the (transient) occurrence of anti-nuclear antibodies in 
numerous forms of tissue injury. As mentioned befor, the TLR9 agonistic activity of 
histones might relate to residual DNA components96. Finally, histones can even act as a DNA 
transfectant by shuttling DNA inside cells110. 
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1.8. Contributions of extracellular histones in the disease setting 
The pathogenic roles of extracellular histones are demonstrated in both infectious and non-
infectious disease conditions, as illustrated in Figure 5 and Table 2, and are described in more 
detail within this section. 
 
 
 
 
Figure: 5. The diagram represents the different pathogenic effects of extracellular histone on variety 
of internal organs like lungs: acute lung injury and COPD; kidneys: acute kidney injury; liver: 
ischemia reperfusion and toxic liver injury; brain: stroke; pancreases: pancreatitis; GIT: peritonitis 
and appendicitis; eye: retinal injury. 
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Table: 2. Current evidence for a functional role of extracellular histones in disease53. 
 
 
Disorder Pathomechanism Ref. 
Infectious disease 
  Sepsis 
 
  Peritonitis/Appendicitis 
 
Histone release promotes sepsis-related endothelial 
dysfunction, tissue hypoxia and death. 
Histones trigger peritoneal inflammation directly by 
activating PRRs and indirectly by inducing cell necrosis 
causing local cytokine production.   
 
10,111 
 
63,112 
Non-infectious disease   
  Trauma Dying cells release histones that injure lng endothelial 
cells causing microvascular thrombosis and haemorrhage. 
89,113,114 
  Thrombosis/embolism Histones trigger thrombosis by inducing endothelial 
activation and by directly inducing thrombin generation 
and platelet aggregation via TLR2 and TRL4. 
93,101,115 
Brain  
    Stroke 
 
Histone neutralization reduces infarct size, while istone 
infusion increases infarct size. 
 
116 
Atherogenesis     Histones bind to LDL. 117 
Lung  
    Acute lung injury 
 
    COPD 
 
Histones from NETting neutrophils that injure endothelial 
cells cause microvascular thrombosis and haemorrhage. 
Hyperacetylated H3 resists degradation and causes injury. 
 
91,113,118 
 
119 
Liver 
   Toxic liver injury     
 
TLR9-mediated hepatotoxicity. 
 
94,120,121 
Kidney  
    Acute kidney injury 
    
    Glomerulonephritis  
 
Microvascular endothelial injury and TLR2/4-mediated 
inflammation leading to acute tubular necrosis. 
NETosis leading to vascular injury in glomeruli. 
 
9,122 
 
25 
Autoimmunity 
    Rheumatoid arthritis/  
    Felty`s syndrome     
 
Citrullinated/deiminated histones serve as autoantige s 
within joint immune complexes. 
 
123,124 
125 
    Systemic lupus Extracellular histones protect slf-DNA from degradation, 
promote auto-immunization together with genetic dead 
cell clearance deficits. 
108,126 
Others   
    Blood transfusion NETosis leading to transfusion f histones, DNA and 
other DAMPs that may cause reactions in recipients. 
127 
    Sickle cell disease  NETs and its componants involved in the pathogenesis 
vaso-occlusive painful sickle cell crisis  
128 
    Hair growth Histones kill hair follicle progenitor cells. 129 
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1.8.1. Sepsis 
Sepsis is a systemic inflammatory response syndrome primarily caused by bacterial 
infections. In 1958, Hirsch et al. observed that histones have a stronger ability to kill bacteria 
than many canonical antimicrobials57. Hyper-inflammatory responses can lead to a variety of 
diseases including sepsis. Esmon CT group reported that extracellular histones released in 
response to inflammatory challenges contribute to endothelial dysfunction, organ failure and 
death during sepsis10. Significant amounts of the histone H3 were increased when E.coli was 
injected into Baboons intravenously, which was associated with septic kidney injury10. In the 
same way, lipopolysaccharide (LPS)-induced AKI also involves the contribution of histones 
because this effect can be completely reversed by the administration of the neutralizing 
histone antibody or activated protein c (aPC)9. Antibodies for histones can reduce the 
mortality of mice in LPS, TNF or cecal ligation and puncture models of sepsis10. 
1.8.2. Thrombosis and intravascular coagulopathy 
Coagulation is the biological process by which blood f rms clots. A control mechanism, 
which fails to coagulate blood results in an increased risk of bleeding (haemorrhage) or 
obstructive clotting (thrombosis). Several studies r port that extracellular histones were 
cytotoxic to endothelial cells, which further contributes to the formation of clots and 
thrombosis in the microvasculature during many disor ers. This was confirmed when 
histones were intravenously injected into mice, which resulted in complications such as 
thrombocytopenia, prolonged prothrombin time, decreased fibrinogen, fibrin deposition in the 
microvasculature and bleeding101,115. Histone-induced TLR2/4 receptor activation is one of 
the main reasons by which platelets aggregate and plasma thrombin is generated93. This 
process can be inhibited by recombinant thrombomodulin that binds to histones and protects 
against thrombosis115. It is possible that in platelets histones raise th  intracellular calcium 
concentrations triggering the activation of αIIbβ3, which further activates the aggregation of 
platelets101. As, because histones are able to bind the platelet adhesion molecules fibrinogen 
and vWF, they are well equipped to stimulate platelet aggregation101. Platelet-deficient mice 
are protected from histone-induced indicating that pl elet thrombi contribute to fatal lung 
injury upon intravenous injection of histones101. 
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1.8.3. Lung diseases 
Approximately half of the patients with ALI/ARDS show the presence of histones in their 
bronchial alveolar fluid (BALF). Ward PA group showed that injection of calf thymus 
histones directly into the lungs via the intratracheal route activates the complement system 
leading to increased histone levels in ALI. They further reported that histones outside of cells 
were highly cytotoxic for alveolar epithelial cells promoting tissue damage and inflammation; 
such effects were reversed by the blockade of histone  in-vivo118. A recent study has linked 
circulating histones with trauma-associated ALI/ARDS and mortality113. These findings were 
consistent with mouse trauma models that displayed pulmonary oedema, haemorrhage, 
microvascular thrombosis and neutrophil congestion113. The dying airway cells also release 
extracellular histones, which further contributes to the development of chronic obstructive 
pulmonary disease. Several nuclear proteins that are known to affect gene expression are 
elevated in the lungs of subjects with COPD, the most n table being those that belong to the 
core histones, especially H3.3. Relative to control subjects, the lung samples from subjects 
with COPD showed increased H3.3 in the extracellular spaces, cellular debris, airway lumen 
mucous, BALF and plasma119. 
1.8.4. Brain, liver and kidney disease 
The mechanisms of histone release into the circulation is a consequence of cell death of 
neurons, liver cells or kidney parenchymal cells, either due to the ischemia reperfusion or 
toxic injury of the organs. The locally released histones further promote the microvascular 
and parenchymal injury. Blocking released extracellular histones using the neutralizing 
histone antibody or other histone blocking agents protects from post ischemic injury in the 
brain, liver and kidney9,96,116,130. Histones released through NETs formation usually cause 
microvascular complications in organs such as liver, brain and kidneys, but a direct effect has 
not been proven yet122. Previous experiments have demonstrated a role for NETs-associated 
toxicity during glomerulonephritis, a mechanism that s been shown for ANCA-associated 
small vessel vasculitis affecting the glomerular compartment of the kidney25. In these organs 
histones mediate their toxic effects by partially activating TLRs and alos mediate it’s 
immunopathology via the activation of NLRP3 inflammasome9,98.  
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1.8.5. Autoimmune disorders 
A recent report has shown the involvement of NETs and its components in activating 
plasmacytoid dendritic cells during the pathogenesis of SLE131. In SLE patients, NETs that 
are released following infection do not rapidly getd graded and cleared from the circulation, 
which could further lead to increased lupus precipitations108,132. NETting neutrophils also 
induce endothelial damage, infiltrate tissues and release immunostimulatory molecules during 
SLE133. Persistent chromatin particles in the extracellular space not only provide 
immunostimulatory DAMPs but also act as autoantigens. Histones are important lupus 
autoantigens, mainly within the nucleosomes; hence, extracellular histones enforce 
autoantigen-presentation and activation of autoreactive lymphocyte clones42,131. Histone H1 
constitutes a major B cell and T cell autoantigens in SLE triggering a pro-inflammatory Th1 
response and driving autoantibody production134. Histones have also been reported to 
stimulate and accelerate the progression of rheumatoid rthritis, whereby protein microarray 
and tandem mass spectrometry analysis of the synovial joint tissue from patients with 
rheumatoid arthritis identified histone H2A and H2B within immune complex deposits along 
the cartilage surface125. Deimination and citrullination of hisones by the ydrolase family of 
enzymes like protein arginine deiminases present in the NETs increase the antigenicity of 
NETosis-derived histones123,135,136. Elevated levels of TNF-α drive the citrullination of 
histone H3, which plays an important role in multiple sclerosis137. Besides acting as direct 
autoantigens in autoimmune disorders, extracellular histones can prevent DNA degradation 
through formation of histone–DNA complex, which enha ce autoimmune responses108. 
 
1.9. Extracellular histones as therapeutic target 
Amongst many DAMPs, histones represent one of the major danger signals during tissue 
injury and disease progression. However, their potential to amplify tissue injury by killing 
other cells in addition to their agonistic activity on TLRs and the NLRP3 inflammasome 
provides a rationale to target histones for therapy. Three histone-neutralizing agents have 
been identified to degrade and neutralize extracellular histone toxicity and of being able to 
prevent histone-related pathologies in-vitro and in-vivo: the histone-neutralizing antibody 
BWA39,10,90,91,138, the serum protease activated protein C (aPC) 9,10,90and heparin93,101,139,140.  
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1.9.1. Histone-neutralizing antibody BWA3 
A histone neutralizing monoclonal antibody was obtained by culturing BWA3 hybridoma 
cells that was first described and confirmed by M. Monestier in 1993141. Since then several 
experimental studies were carried out using the neutralizing antibody from the BWA3 clone 
and showed its effect in several disease models. BWA3 binds to an epitope corresponding to 
a region of high sequence similarity between H2A and H4. The therapeutic effect of the 
histone antibody was first reported by Xu J et al. during sepsis10. Since then other groups 
have reported the therapeutic property of BWA3 in many other diseases, which have been 
discussed in section 1.8. 
1.9.2. Activated protein C  
aPC is classified as a serine protease because it contains a residue of serine at its active 
site142. aPC is a vitamin K-dependent plasma protein zymogen that is synthesized in the liver, 
whose genetic, mild or severe deficiencies are linked with a risk for venous thrombosis or 
neonatal purpura fulminans, respectively142-144. Over the past decades, studies have shown 
that aPC inactivates factor Va and VIIIa to down-regulate thrombin generation. More 
recently, basic and preclinical research on aPC has c racterized the direct cytoprotective 
effects that involve gene expression profile alterations, anti-inflammatory and anti-apoptotic 
activities and endothelial barrier stabilization145,146. These protective functions of aPC are 
mainly due to the activation of the angiopoietin/Tie2 axis and the modulation of EPCR-bound 
lipids145,146. Many studies reported that aPC has the capacity to cleave the released 
extracellular histones indicating that aPC has cytoprotective and anti-inflammatory 
actions89,90,147, for example, during sepsis10 and ischemic injury in the brain, liver and 
kidney9,96,116. However, the activity of aPC in-vivo seems limited in blocking NETosis-
induced histone toxicity, even though this protease has certainly additional biological 
effects91. A clinical trial in children with meningococcal sepsis, histone plasma levels 
correlated with the disease severity, but recombinant aPC therapy did not affect these 
levels148. Although recombinant aPC had first been approved by the FDA for the treatment of 
human sepsis, it was later withdrawn from the market due to a lack of efficacy in reducing 
sepsis mortality in a subsequent randomized controlled trial149. 
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1.9.3. Heparin 
Heparin is a highly sulphated glycosaminoglycan that is widely used as an injectable 
anticoagulant and has the highest negative charge density of any known biological molecule. 
As histones carry a strong positive charge, it is po sible that histones have a strong affinity to 
the negatively charged heparin triggering the formation of a complex due to the electrostatic 
interactions of the high affinity150. It is, however not known whether binding of heparin to 
histones also protects against the cytotoxic effect of histones on endothelial cells. In this 
thesis and this was reported before by several groups that, heparin has beneficial effects on 
histone neutralization and elicits cytoprotective effects. Only moderate doses of heparin can 
attenuate injuries, whereas high doses of heparin are h rmful due to the complication of 
disseminated hemorrhage151-153. It is reasonable to suggest that chemically modifie  heparin 
derivatives, devoid of anticoagulant activity, may be more useful than heparin for controlling 
inflammation caused by histones. 
 
1.10. Rapid progressive glomerulonephritis 
Rapidly-progressive glomerulonephritis (RPGN) encompasses a heterogeneous group of 
disorders resulting in severe glomerular inflammation and injury. Clinically, RPGN is 
characterized by a rapid loss of glomerular filtration rate, haematuria and proteinuria caused 
by characteristic glomerular lesions such as capillary necrosis and hyperplasia of the parietal 
epithelial cells (PEC) along Bowman`s capsule forming crescents. The pathogenesis of 
RPGN involves autoantibodies, immune complex-mediat activation of complement, the 
local production of cytokines and chemokines, and glomerular leukocyte recruitment154. 
RPGN often manifests as necrotizing and crescentic GN, such as seen in anti-neutrophil 
cytoplasmic antibody (ANCA)-associated renal vasculitis or anti-GBM disease (e.g. 
Goodpasture syndrome). All these forms are associated with neutrophil-induced glomerular 
injury24,155-157. In situations where the stimuli persistently trigger inflammation, an increasing 
number of leucocytes and neutrophils will infiltrate into the injured area158. In the presence of 
local cytokines released due to the inflammatory or infectious stimuli, these infiltrated 
neutrophils gets activated and form NETs, these are comprised of extracellular fibrillary 
material containing chromatin and granule proteins a d numerous DAMPs including histones 
will be released159,160.  
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Necrotizing injury to vessel walls results in haemorrhage and the release of plasma proteins 
into the vessel walls and adjacent extravascular tissue161 (Figure 6). These proteins include 
coagulation factors, which are activated by thrombogenic cellular and tissue debris, and tissue 
factors, which result in the formation of fibrin within areas of fibrinoid necrosis162. This leads 
to severe platelet activation and fibrotic clot formation within the microvasculature causing 
hypoxia in the local areas of the glomeruli, which can further lead to cell death-associated 
release of DAMPs and continues during the necrotizing or crescentic glomerulonephritis. It is 
possible that the fibrin formation is facilitated by tissue factors present in NETs in glomeruli. 
Foci of segmental fibroid necrosis develop adjacent cellular reactions (as in crescents) 
composed predominantly of monocytes, macrophages and activated epithelial cells157. 
 
 
 
Figure: 6. Leukocytoclastic venulitis caused due to the infiltrating leukocytes cause endothelial 
damage by fibrinoid necrosis resulted in thrombotic vascular occlusions this further leads to the 
hypoxia and organ failure (left image). Necrotizing glomerulonephritis involves vascular damage and 
sclerosis (right image)  
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1.10.1. Anti-GBM glomerulonephritis 
Anti-GBM disease also called “Goodpasture's disease” is one of the three major forms of 
RPGN. Here, the loss of tolerance with production of GBM autoantibodies described against 
the noncollagenous-1 (NC1) domain of type 4 collagen of GBM membrane and kill the 
glomerular cells in a complement-dependent manner163,164. Although some patients present 
initially with relatively mild renal insufficiency, the disorder is typically associated with 
severe renal injury that, if left untreated, progresses quickly to end-stage renal disease 
(ESRD)165,166. 
1.10.2. Epidemiology 
It’s been reported that, the disease has an estimated incidence of one case per 2 million per 
year in European caucasian populations. It is responsible for 1 to 5% of all types of GN and is 
the cause in 10 to 20% of patients with crescentic GN. All age groups are affected but the 
peak incidence is in the third decade in young men with a second peak in the sixth and 
seventh decades affecting men and women equally. Lung haemorrhage is more common in 
younger men, while isolated renal disease is more frequent in the elderly with near equal 
gender distribution. 
1.10.3. Diagnosis 
• The diagnosis of Goodpasture's disease is dependent on the detection of anti-GBM 
antibodies either in the circulation or in kidney tissue. 
• Renal biopsy to detect the severity of the lesions. The antibodies can also be detected 
on renal biopsy specimens with characteristic linear st ining for IgG and frequently 
C3 detected along the GBM 
1.10.4.  Treatment 
It has been observed that neither steroids nor immunos ppressive drugs had an influence on 
the renal outcome. However, the recommended treatment approaches are listed in the table 
below (Table: 3). 
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Table: 3. Recommended treatment approaches for GN167 
Treatment Description 
Plasma exchange 4-L exchanges daily with human albumin as replacement solution. Where 
there is risk of hemorrhage FFP should be given at the end of the 
procedure.  
Corticosteroids Prednisolone 1 mg/kg for first week then reduce at weekly intervals to 45, 
30, 25, 20, 15, 10, and 5 mg. 
Cytotoxic drugs Cyclophosphamide 3 mg/kg rounded down to nearest 50 mg. In patients 
over 55 yr of age, use 2 mg/kg rounded down to nearest 25 mg 
aFFP, fresh frozen plasma.  
 
There have been many studies that have explored the functional role of the immune complex 
deposition and/or chemokines and cytokines involved in the progression of severe 
glomerulonephritis168-170. However, limited research has been undertaken to es ablish new 
and effective methods to control the progression of gl merulosclerosis. This thesis will 
addresses novel pathomechanisms involved in the progression of glomerulosclerosis and 
provide important insights into the development of effective and safe treatments.  
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2. Hypotheses 
An important characteristic feature of severe GN is necrosis of the glomerular tuft cells, so 
we hypothesized that there will be extensive releas of DAMPs including histones. The 
disease is also characterized by infiltration of neutrophils and release of cytokines, in this 
condition we speculated the formation of NETs and release of more histones in to the 
extracellular space. 
Accordingly, the specific objectives and aims of this study were: 
 
1. To investigate, whether extracellular histones elicit toxic effects on glomerular 
endothelial cells (GEnC) and whether they promote truft necrosis, proteinuria and 
crescent formation during experimental glomerulonephritis. 
 
2. To investigate the effect of extracellular histones using histone blocking agents such 
as neutralizing anti-histone antibody, heparin and aPC during severe 
glomerulonephritis. 
 
3. To evaluate NETs-related histones and to determine the fficacy of blocking NETosis 
using the Peptidylarginine deiminase (PAD)-4 inhibitor during the progression of 
severe glomerulonephritis. 
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3. Materials and Methods 
3.1 Instruments and Chemicals 
3.1.1 Instruments 
Balance:  
Analytic Balance, BP 110 S Sartorius, Göttingen, Germany 
Mettler PJ 3000 Mettler-Toledo, Greifensee, Switzerland 
 
Cell Incubator: 
 
Type B5060 EC-CO2 Heraeus Sepatech, München, Germany 
 
Centrifuges: 
 
Heraeus, Minifuge T VWR International, Darmstadt, Germany 
Heraeus, Biofuge primo Kendro Laboratory Products GmbH, Hanau, 
Germany 
Heraeus, Sepatech Biofuge A Heraeus Sepatech, München, Germany 
 
ELISA-Reader: 
 
Tecan, GENios Plus Tecan, Crailsheim, Germany 
 
Fluorescence Microscopes: 
 
Leica DC 300F Leica Microsystems, Cambridge, UK 
Olympus BX50 Olympus Microscopy, Hamburg, Germany 
 
Spectrophotometer: 
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Beckman DU® 530 Beckman Coulter, Fullerton, CA, USA 
TaqMan Sequence Detection 
System: 
 
ABI prism ™ 7700 sequence 
detector 
qRT-PCR syber green  LC-480                                                          
PE Biosystems, Weiterstadt, Germany 
 
Roche, Mannheim, Germany 
 
Other Equipments: 
 
Nanodrop PEQLAB Biotechnology GMBH, Erlangen, Germany 
Cryostat RM2155 Leica Microsystems, Bensheim, Germany 
Cryostat CM 3000 Leica Microsystems, Bensheim, Germany 
Homogenizer ULTRA-TURRAX 
T25 
IKA GmbH, Staufen, Germany 
Microtome HM 340E Microm, Heidelberg, Germany 
pH meter WTW WTW GmbH, Weilheim, Germany 
Thermomixer 5436 Eppendorf, Hamburg, Germany 
Vortex Genie 2™ Bender & Hobein AG, Zürich, Switzerland 
Water bath HI 1210 Leica Microsystems, Bensheim, Germany 
 
3.1.2 Chemicals and Reagents 
RNeasy Mini Kit Qiagen GmbH, Hilden, Germany 
RT-PCR primers Metabion, Munich, Germany 
 
Cell culture: 
 
DMEM-medium Biochrom KG, Berlin, Germany 
RPMI-1640 medium GIBCO/Invitrogen, Paisley, Scotland, UK 
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FCS Biochrom KG, Berlin, Germany 
Dulbecco’s PBS (1×) PAN Laboratories GmbH, Cölbe, Grmany 
Trypsine/EDTA (1×) PAN Laboratories GmbH, Cölbe, Germany 
CD hybridoma media GIBCO/Invitrogen, Paisley, Scotland, UK 
FBS, ultralow IgG PAN Laboratories GmbH, Cölbe, Germany 
Glutamine  PAN Laboratories GmbH, Cölbe, Germany 
Penicillin/Streptomycin (100×) PAN Laboratories GmbH, Cölbe, Germany 
Matrigel BD biosciences, Heidelberg, Germany 
  
Drugs and treatment:  
Heparin Ratiopharma, Ulm, Germany 
Cl-amide (PAD inh) Millipore, Darmstadt, Germany 
aPC Lilly, UK 
 
Antibodies: 
 
Anti-histone antibody Homemade BWA3 clone 
Neutrophil elastase Abcam, Cambridge, UK 
MPO Abcam, Cambridge, UK 
Fibrinogen Abcam, Cambridge, UK 
TNF-α Abcam, Cambridge, UK 
WT-1 Cell signaling, Danvers, MA 
Mac-2 Cedarlane, ON, Canada 
HRP linked Anti-Rabbit secondary 
Ab 
Cell signaling, Danvers, MA 
HRP linked Anti-Mouse secondary 
Ab 
Cell signaling, Danvers, MA 
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HRP linked Anti-Goat secondary Ab Dianova, Hamburg, Germany 
β-Actin Cell signaling, Danvers, MA 
α-tubulin Cell signaling, Danvers, MA 
Tamm–Horsfall protein Santa Cruz Biotechnology, Santa Cruz, CA 
Lotus tetragonolobus lectin Vector Labs, Burlingame, CA 
rat anti-mouse neutrophils Serotec, Oxford, UK 
CD3+ AbD Serotec, Düsseldorf, Germany 
F4/80+ AbD Serotec, Düsseldorf, Germany 
Claudin Bioworld technology, CB8 7SY England 
Nephrin Acris Antibodies GmbH, Herford, Germany 
Ki-67 Dako Deutschland GmbH, Hamburg, Germany 
α-SMA Dako Deutschland GmbH, Hamburg, Germany 
 
Elisa and assay Kits: 
 
mouse IL-6 R &D Systems, Minneapolis, MN, USA 
mouse TNF-α Biolegend, San Diego, CA 
mouse Albumin Bethyl Laboratories, TX, USA 
Creatinine FS DiaSys Diagnostic System, GmBH, Holzheim, 
Germany 
Urea FS DiaSys Diagnostic System, GmBH, Holzheim, 
Germany 
 
Chemicals: 
 
Acetone Merck, Darmstadt, Germany 
AEC Substrate Packing Biogenex, San Ramon, USA 
Bovines Serum Albumin Roche Diagnostics, Mannheim, Germany 
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Skim milk powder Merck, Darmstadt, Germany 
DEPC Fluka, Buchs, Switzerland 
DMSO Merck, Darmstadt, Germany 
Diluent C for PKH26 dye Sigma-Aldrich Chemicals, Germany 
EDTA Calbiochem, SanDiego, USA 
30% Acrylamide Carl Roth GmbH, Karlsruhe, Germany 
TEMED Santa Cruz Biotechnology, Santa Cruz, CA 
Eosin Sigma, Deisenhofen, Germany 
Ethanol Merck, Darmstadt, Germany 
Formalin Merck, Darmstadt, Germany 
Hydroxyethyl cellulose Sigma-Aldrich, Steinheim, Germany 
HCl (5N) Merck, Darmstadt, Germany 
Isopropanol Merck, Darmstadt, Germany 
Calcium chloride Merck, Darmstadt, Germany 
Calcium dihydrogenphosphate Merck, Darmstadt, Germany 
Calcium hydroxide Merck, Darmstadt, Germany 
MACS-Buffer Miltenyl Biotec, Bergisch Gladbach, Germany 
Beta mercaptoethanol Roth, Karlsruhe, Germany 
Sodium acetate Merck, Darmstadt, Germany 
Sodium chloride Merck, Darmstadt, Germany 
Sodium citrate Merck, Darmstadt, Germany 
Sodium dihydrogenphosphate Merck, Darmstadt, Germany 
Penicillin Sigma, Deisenhofen, Germany 
Roti-Aqua-Phenol Carl Roth GmbH, Karlsruhe, Germany 
Streptomycin Sigma, Deisenhofen, Germany 
Tissue Freezing Medium Leica, Nussloch, Germany 
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Trypan Blue Sigma, Deisenhofen, Germany 
Oxygenated water DAKO, Hamburg, Germany 
Xylol Merck, Darmstadt, Germany 
 
Miscellaneous: 
 
Cell death detection (TUNEL) kit Roche, Mannheim, Germany 
Microbeads Miltenyl Biotech, Germany 
Cell Titer 96 Proliferation Assay  Promega, Mannheim, Germany 
LS+/VS+ Positive selection columns Miltenyl Biotec, Bergish Gladbach, Germany 
Preseparation Filters Miltenyl Biotec, Bergish Gladb ch, Germany 
Super Frost® Plus microscope slides  Menzel-Gläser, Braunschweig, Germany 
Needles BD Drogheda, Ireland 
Pipette’s tip 1-1000μL Eppendorf, Hamburg, Germany 
Syringes Becton Dickinson GmbH, Heidelberg, Germany 
Plastic histocasettes NeoLab, Heidelberg, Germany 
Tissue culture dishes Ø 100x20mm TPP, Trasadingen, Switzerland 
Tissue culture dishes Ø 150x20mm TPP, Trasadingen, Switzerland 
Tissue culture dishes Ø 35x10mm Becton Dickinson, Franklin Lakes, NJ, USA 
Tissue culture flasks 150 cm2 TPP, Trasadingen, Switzerland 
Tubes 15 and 50 mL TPP, Trasadingen, Switzerland 
Tubes 1.5 and 2 mL TPP, Trasadingen, Switzerland  
All other reagents were of analytical grade and are commercially available from Invitrogen, 
SIGMA or ROCH. 
All the FACS antibodies were used from BD Biosciencs, eBiosciences or BIO-RAD.  
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3.2 Experimental procedures 
3.2.1 Animals 
C57BL/6N wild-type mice obtained from Charles River (Sulzfeld, Germany). All mice were 
housed in poly-propylene cages under standard conditi s with the temperature of 22±20C 
with 12 hours light and dark cycle. Water and standard chow diet (Sniff, Soest, Germany) 
were available ad libitum for the complete duration of the study. Cages, bedding, nestles, 
food, and water were sterilized by autoclaving befor  use. All the aspects of animal handling 
and experiments were approved by the Regierung von Oberbayern. 
 
3.2.2 Animal models 
GBM anti-serum induced glomerulonephritis168 
Glomerulonephritis was induced in the wild type C57BL/6N mice by a single intravenous 
injection of 100 µl of GBM anti-serum (Probetex, San Antonio, TX). The induction of the 
disease can be seen by increased albuminuria within 24 hours after anti-serum injection. All 
the animals were sacrificed on day 7, urine and blood were collected for the analysis of 
functional parameters and kidneys were harvested for histology, protein, mRNA and FACS 
analysis. Anti-serum contains antibodies against the GBM, this directly binds GBM and 
micro-vasculature in the glomeruli leading to the activation of the complement system 
followed by glomerular and endothelial cell death, as illustrated in Figure 7. This leads to the 
release of abundant amounts of intracellular contents including DAMPs like histones and 
results in the infiltration of immune cells especially neutrophils and macrophages leading to 
the secretion of inflammatory cytokines and chemokines168.  
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Figure: 7. Schematic represents of stages of GBM antiserum induced glomerulonephritis and DAMPs 
release. 
 
3.2.3 Experimental design 
To study the effect of histone neutralization in the anti-GBM glomerulonephritis model, we 
used anti-histone IgG as a potential therapy, which as capacity to neutralize extracellular 
histones. To do so we used different strategies:  
a) Prophylactic of anti-histone IgG 
b) Therapeutic administration of anti-histone IgG   
c) Other histone neutralizing agents such as heparin, PC or blocking NETosis with Cl-amide 
d) A combination of anti-histone IgG, heparin and aPC.  
The therapeutic and prophylactic administration schedules are illustrated in figure 8. 
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a) Prophylactic administration with anti-histone IgG 
 
In this experimental setting, mice received an i.p. injection of 20 mg/kg anti-histone IgG or 
control IgG 24h prior to the administration of anti-GBM serum followed by treatment with 
anti-histone IgG on day 1 and 3 (Figure 8). On day 7, urine and blood were collected to 
analyze the functional parameters, like BUN, plasma creatinine and albuminuria, later mice 
were sacrificed and kidneys harvested for histology, mRNA and FACS analysis. 
 
b) Therapeutic administration with anti-histone IgG 
 
For the therapeutic treatment, mice were injected with anti-GBM serum (100 μl/animal) and 
treatment with anti-histone IgG was initiated only after the onset of GN (i.e., after induction 
of proteinuria) on day 2, 4 and 6. On day 7, urine a d blood were analyzed for functional 
parameters as well as albuminuria, and the kidneys harvested for histology, mRNA and 
FACS analysis.  
 
c) Therapeutic administration with heparin, aPC or Cl-amide 
 
Mice received an injection of 100 µl anti-GBM serum prior to the daily administration of 
heparin (50 IU/mice, i.p.), aPC (5 mg/kg, i.p.) or Cl-amide (10 mg/kg, i.p.)  for up to 7 days. 
Sample analysis was performed as stated in the Prophylactic treatment of anti-histone IgG 
regime (section 3.2.3 a).   
 
d) Combination of anti-histone IgG, heparin and aPC 
 
Here, mice were treated with a combination of anti-histone IgG (20 mg/kg, i.p. on day 2, 4 
and 6), heparin (50 IU/mice, i.p., daily) and/or aPC (5 mg/kg, i.p., daily) 48 hours after the 
injection of  anti-GBM serum (100 µl). Samples were collected on day 7 and prepared like in 
section 3.2.3 a).   
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Prophylactic treatment :
α-Histone IgG 20 mg/kg, i.p.
α-Hist. IgG
Day    -1 0 1 3 7
Anti-GBM @
100µl/Animal
Sacrifice the animals , Histo and FACS
α-Hist. IgG α-Hist. IgG
 
Prophylactic administration (n=6) 
 
 
 
 
Therapeutic administration (n=6) 
 
 
Figure: 8. Schematics showing the treatment schedules for prophylactic and therapeutic treatment 
with anti-histone IgG 
 
3.3 Blood and urine sample collection 
Mice were anesthetized using isoflurane at a rate of 2.5 % with an oxygen flow of 2 l/h and 
blood was drawn from the facial vein using micro lancet and blood collected into centrifuge 
tubes containing EDTA (10 μl of 0.5 M solution per 200 μl of blood). Blood samples were 
centrifuged at 8000 rpm for 5 min and plasma collected and stored at -200C until further use.  
Urine samples were collected at different times during the experimental time course as well 
as at the end of the study. All samples were stored at -200C until used for further analysis.  
 
Therapeutic treatment :
α-Histone IgG 20 mg/kg, i.p.
α-Hist. IgG
Day    0 1 2                         4                                 6                 7
Anti-GBM @
100µl/Animal
Sacrifice the animals , 
Histo and FACS
α-Hist. IgG α-Hist. IgG
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3.4 Urinary albumin to creatinine ratio 
3.4.1 Urinary albumin 
Urinary albumin levels were determined using an albumin ELISA kit from Bethyl 
Laboratories according to manufacturer’s instructions. One hallmark of the glomerular 
disease is the abundant amount of protein excreted through the urine due to the loss of 
endothelial cells and glomerular basement membrane barrier leading to increased excess 
levels of albumin in the urine. In this study, urine samples were diluted 104 to 106 times with 
the assay diluent before estimation. Briefly, capture antibody (goat anti-mouse albumin, 
1:100) was diluted in coating buffer (carbonate-bicarbonate, pH 9.6) and coated with 100µl 
of diluted antibody onto a Nunc Maxisorb flat bottom 96-well plate and incubated overnight 
at 40C. Plate was then washed 3 times with wash buffer (Tris NaCl with Tween 20) and 
blocking solution (Tris, NaCl with 1% BSA, pH 8) added for 1 hour at room temperature. 
Following blocking, the plate was washed 3 to 5 times with wash buffer and diluted 
samples/standards were then added in the respective wells and incubated for 1 hour. After 
incubation, each well was washed 5 times with wash buffer and HRP-conjugated detection 
antibody (dilution of 1:75000) was added and the plate was incubated in dark for 1 hour. 
After HRP-conjugate incubation, each well was washed 5 to 7 times with wash buffer and 
TMB reagent (freshly prepared by mixing equal volumes of two substrate reagents) was 
added and the samples incubated in dark until color reaction was completed (for 5 minutes) 
followed by addition of the stop solution (2 M H2SO4). The absorbance was read at 450 nm 
within 10 minutes following addition of the stop solution. The albumin content in each 
sample was determined using the equation of regression line generated by plotting 
absorbance of different standards against their known concentrations.  
 
3.4.2 Urinary creatinine, plasma creatinine and plasma BUN 
Urinary creatinine and plasma creatinine levels were measured by Jaffe´s enzymatic reaction 
using a Creatinine FS kit (DiaSys Diagnostic system, G BH, Holzheim, Germany). Urine 
samples were diluted 10 times with distilled water, whereas plasma samples were used 
undiluted. Serial dilutions of the standard were prpared using the stock provided in the kit. 
Working monoreagent was prepared by mixing 4 part of eagent 1 (R1) and 1 part of reagent 
2 (R2). Then, 10 μl of each of the diluted samples and standards wereadd d to a 96-well flat 
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bottom plate (Nunc maxisorb plate). The monoreagent (200 µl) was added to each well and 
the reaction mixture incubated for one minute before measuring the absorbance at 492 nm 
immediately (1 (A1) and 2 (A2) minutes after addition) using an ELISA plate reader. The 
change in absorbance (Δ A) was calculated as Δ A = [(A2 – A1) sample or standard] – [(A2 – 
A1) blank]. And creatinine content in the samples was calculated as: 
Creatinine (mg/dl) = ΔA sample /ΔA standard x Concentration of standard (mg/dl) 
Plasma BUN levels were measured using a Urea FS kit (DiaSys Diagnostic system, GmBH, 
Holzheim, Germany). Serial dilutions of standard were prepared using the stock provided 
with the kit. Working monoreagent was prepared by mixing 4 part of reagent 1 (R1) and 1 
part of reagent 2 (R2) provided in the kit. Then, 2 μl of each of the sample and standards were 
added to a 96-well flat bottom plate (Nunc maxisorb plate). The monoreagent (200µl) was 
added to each well and the reaction mixture incubated for one minute before measuring the 
absorbance  at 360 nm immediately after 1 (A1) and 2 (A2) minutes using an ELISA plate 
reader. The change in absorbance (Δ A) was calculated as Δ A = [(A1 – A2) sample or 
standard] – [(A1 – A2) blank]. And BUN content in the samples was calculated as: 
BUN (mg/dl) = ΔA sample /ΔA standard x Concentration of standard (mg/dl)x0.467 
The urinary albumin to creatinine ratio was calculated after converting values for albumin 
and creatinine to similar units (mg/dl). Albumin content for each sample calculated (mg/dl) 
was divided by creatinine content (mg/dl) for the same sample. 
 
3.5 Cytokines ELISA 
All cytokine levels in the supernatants collected from in-vitro cell stimulation assays were 
measured using ELISA kits in accordance with the manuf cturer’s instructions. Briefly, the 
NUNC ELISA plates were captured with the capture antibody in coating buffer overnight at 
4°C. On the next day, the plates were washed 3 times with washing buffer and non-specific 
binding blocked with either the blocking solution or assay diluent for 1 hour. Following 
washing, the standards, samples and sample diluent (blank) were added into the wells and 
incubated at RT for 2 hours. After 2 hours, plates were washed 5 times and the HRP/AP 
conjugated secondary antibody diluted in assay diluent was added and incubated for 1 hour. 
The plates were washed 5-7 times and incubated with 100 μl of substrate A and B (1:1 
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mixture) for 25-30 minutes in the dark. The reaction was stopped by addition of 100 μl of 1 
M H2SO4. The absorbance was measured at 450 nm and the refer nce wavelength was 620 
nm using a spectrophotometer (TECAN-Genios Plus). 
 
3.6 Immunostaining and confocal imaging 
For immunohistological analysis, the middle part of he kidney from each mouse was fixed in 
formalin (10 % in PBS or Saline) over night, than processed using tissue processors (Leica) 
and the paraffin blocks prepared. 2 µm thick paraffin-embedded sections were cut. De-
paraffinization was carried out using xylene (3x 5 minutes) followed by re-hydration, which 
was carried out by incubating the sections in 100% absolute ethanol (3x 3 minutes), 95% 
ethanol (2x 3 minutes) and 70% ethanol (1x 3 minutes) followed by washing with PBS (2x 5 
minutes). Blocking of endogenous peroxidase was carried out by incubating sections in H2O2 
and methanol mixture (20 ml of 30% H202 in 180 ml of methanol) for 20 minutes in dark 
followed by washing in PBS (2x 5 minutes). For unmasking of antigen, sections were dipped 
in antigen unmasking solution (3 ml of antigen unmasking solution + 300 ml of distilled 
water) and cooked in the microwave for 10 minutes (4x 2.5 minutes, every 2.5 minutes water 
level was checked and made up to the initial levels with distilled water every time). After 
microwave cooking, the sections were cooled to room te perature for 20 minutes and then 
washed with PBS. Blocking endogenous biotin, we incubated the sections with one drop of 
Avidin (Vector) for 15 minutes followed by incubation with Biotin (Vector) for an additional 
15 minutes. After incubation, sections were washed with PBS (2x 5 minutes). 
Next, sections were incubated with different primary ntibodies either for 1 hour at room 
temperature or overnight at 40C in a wet chamber followed by wash steps with PBS (2x 5 
min). After washing, sections were incubated with the appropriate biotinylated secondary 
antibodies (1:300, dilution in PBS) for 30 minutes followed by wash steps with PBS (2x 5 
minutes). Substrate solution (ABC solution, Vector) was added and sections were incubated 
for 30 minutes at room temperature in a wet chamber followed by wash steps with PBS (1x 5 
minutes). Tris buffer saline (1x 5 minutes) and sections were stained for DAB followed by 
counter staining with methyl green (Fluka). Then sections were washed with alcohol (96 %) 
to remove excess stain and xylene and then dried and mounted with VectaMount (Vector). 
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The primary antibodies used in the study are mentioned above (section 3.1.2). For each 
immunostaining, negative controls were performed by incubation with the respective isotype 
antibody instead of the primary antibody. 
For confocal imaging, the sections, prepared as describ d above, were incubated with the 
following primary antibodies: pig anti-mouse nephrin (1:100, Acris Antibodies, Herford, 
Germany), rabbit anti-mouse WT1 (1:25, Santa Cruz Biotechnology, Santa Cruz, CA) and 
rabbit anti-mouse MDM2 (1:100, Abcam, Cambridge, UK) and biotinylated lotus 
tetragonolobus lectin (Vector Labs, CA, USA) for 1 hour in PBS or 0.1 % milk solution at 
room temperature. After washing, the sections were incubated with the secondary antibodies: 
guinea pig Alexa Fluor 488 (1:100, Invitrogen, Carlsbad, CA) or rabbit Cy3 (1:200, Jackson 
ImmunoResearch Laboratories, West Grove, PA) for 30 minutes at room temperature. The 
antibody staining of the sections were evaluated using the confocal microscope LSM 510 and 
the LSM software (Carl Zeiss AG). 
3.7 Periodic acid-Schiff staining 
Formalin-fixed tissues were processed using tissue processors (Leica) and the paraffin blocks 
were prepared. 2 µm thick paraffin-embedded sections were cut. De-paraffinization was 
carried out using xylene (3x 5 minutes) followed by re-hydration by incubating the sections 
in 100% absolute ethanol (3x 3 minutes), 95% ethanol (2x 3 minutes) and 70% ethanol (1x 3 
minutes) followed by washing with distilled water (2x 5 minutes). Re-hydrated sections were 
incubated with Periodic acid (2 % in distilled water) for 5 minutes followed by washing with 
distilled water (1x 5 minutes). Then sections were incubated with Schiff solution for 20 
minutes at room temperature followed by washing with tap water (1x 7 minutes) and counter 
staining with Hematoxylin solution (1x 2 minutes). This was followed by washing with tap 
water (1x 5 minutes) and finally sections were dipped in 90% alcohol, dried and the sections 
closed with cover slips. 
 
3.8 Histopathological evaluations 
3.8.1 PAS staining 
All kidney sections were quantified for PAS scoring and values were expressed as mean ± 
SEM. Glomerular sclerotic lesions were assessed using a semi quantitative score (as in figure 
9) by a blinded observer as follows, after assessing 50 glomeruli from each section: 
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Figure: 9. Representative images of glomerular lesions  
 
Score Lesion in Glomeruli  
No lesion (0)  None 
Segmental Lesion (1) ≤ 50 %  
Global Lesion (2) ≥ 50 % 
All sections in each group were quantified as percentage of glomeruli with each score (mean 
± SEM). 
 
Tubular injury also was scored in the PAS sections, percentage of tubules in the 
corticomedullary junction that displayed cell necrosis, loss of brush border, cast formation, 
and tubular dilatation as follows:  
Score Injury level 
0 None 
1 ≤ 10% 
2 21 % to 40 % 
3 41 % to 60 % 
4 61 % to 80 % 
5 81 % to 100 % 
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3.8.2  Mac-2 staining 
The number of infiltrated macrophages into the glomeruli was counted in the sections stained 
with Mac-2 (pan marker for macrophage) antibodies. Mac-2 positive cells were counted 
manually in 50 glomeruli from each kidney section and reported as the percentage of Mac-2 
positive cells in each group. 
 
3.8.3 Neutrophils 
The number of infiltrated neutrophils in the glomeruli was counted in the sections stained 
with the Ly-6B.2 antibody. Positive cells were counted manually in 50 glomeruli from each 
kidney section and reported as percentage Ly-6B.2 positive cells per group. 
3.8.4 Podocytes 
Kidney sections were staining with the WT-1/Nephrine antibody, which were labeled with 
Alexa and FITC conjugated secondary antibodies respectively. Double positive cells were 
counted manually in 50 glomeruli and the average number of podocytes was reported in each 
group. Representative pictures were taken on the confo al microscope to support the 
counting. 
 
3.8.5 Myeloperoxidase and CD31 
Kidney sections were stained with Myeloperoxidase (MPO) and CD31 antibody to show the 
presence of NETs within the MPO positive area, which was in close association with 
endothelial cells (CD31 positive area). This staining method shows the cytotoxicity 
associated with NETs on endothelial cells. 
 
3.9 Immunohistochemistry in human tissues  
Formalin-fixed paraffin-embedded sections of renal biopsies from five subjects with ANCA-
positive RPGN, newly diagnosed in 2013, were drawn from the files of the Institute of 
Pathology at the Ludwig-Maximilians-University of Munich. Informed consent was obtained 
in all cases before renal biopsy. The renal biopsies w re fixed in 4 % PBS-buffered formalin 
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solution and embedded in paraffin. Biopsies contained ormal glomeruli and glomeruli 
exhibiting cellular, fibrocellular or fibrous crescents. Controls consisted of normal kidney 
tissue from tumor nephrectomies. TLR2 and TLR4 exprssion was assessed by using specific 
antibodies (TLR2-LS Bio, Seattle, WA, TLR4- Novus, Littleton, CO). 
 
3.10 Electron microscopy 
Kidney tissues and endothelial cell monolayers were fixed in 2.0 % paraformaldehyde/ 2.0 % 
glutaraldehyde, in 0.1 M sodium phosphate buffer, pH 7.4 for 24 hours, followed by 3 washes 
x15 min in 0.1 M sodium phosphate buffer, pH 7.4 and distilled water.  For transmission EM 
kidneys were post-fixed, in phosphate cacodylate-buffered 2 % OsO4 for 1h, dehydrated in 
graded ethanols with a final dehydration in propylene oxide and embedded in Embed-812 
(Electron Microscopy Sciences, Hatfield, PA). Ultrathin sections (~90-nm thick) were stained 
with uranyl acetate and Venable's lead citrate. For scanning EM, after rinsing in distilled 
H2O, cells on coverslips were treated with 1 % thiocarbohydrazide, post-fixed with 0.1 % 
osmium tetroxide, dehydrated in ethanol, mounted on stubs with silver paste and critical-
point dried before being sputter coated with gold/palladium. Specimens were viewed with a 
JEOL model 1200EX electron microscope (JEOL, Tokyo, Japan). 
 
3.11 RNA analysis 
3.11.1 RNA isolation 
Another part of the kidney from each mouse was preserv d in RNA-later immediately after 
kidney isolation and stored at -200C until processed for RNA isolation. RNA isolation was 
carried out using RNA isolation kit from Ambion (Ambion, CA, USA). In short, tissues (30 
mg) preserved in RNA-later were homogenized using blade homogenizer for 30 seconds at 
speed 4 in lysis buffer (600 μl) containing β-mercaptoethanol (10 μl/ml). The homogenate 
was centrifuged at 6000 rpm for 5 minutes and 350 μl of supernatant was transferred into a 
fresh DEPC-treated tube and 70 % ethanol was added and mixed gently. The whole mixture 
was then loaded on a RNA column and processed for RNA isolation as per manufacturer’s 
instruction. Isolated RNA was measured, checked for purity as follows and stored at -800C. 
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3.11.2 RNA quantification and purity check 
The isolated RNA samples were quantified using a Nano drop (PEQLAB Biotechnology 
GMBH, Erlangen, Germany). The ratio of optical densitie  at 260 nm and 280 nm is an 
indicator for RNA purity (indicative of protein contamination in the RNA samples). Only 
samples with a ratio of 1.8 or more were considered to be of acceptable quality. 
3.11.3 RNA integrity check 
A further quality check (if necessary) was performed using a denaturing RNA gel. Briefly, 
2% Agarose gel with Ethidium-bromide was casted, RNA samples were mixed with RNA 
loading buffer (4:1 ratio) (Sigma Aldrich, Germany) and the samples were loaded onto the 
gel. Electrophoresis was carried out at constant volt (70-100 V) using MOBS running buffer 
for 1 hour and the gel was imaged on a gel documentatio  apparatus under a UV lamp. RNA 
samples that show a single bright band were considered to be of good quality. Loss of RNA 
integrity could be detected as smear formation in the Agarose gel (Figure 10). 
 
 
 
Figure: 10. RNA integrity check 
 
3.11.4 cDNA synthesis and real-time RT-PCR (SYBR Green) 
The isolated RNA samples were quantified and processed for cDNA conversion using reverse 
transcriptase II (Invitrogen, Karlsruhe, Germany). RNA samples were diluted in DEPC 
treated tubes containing water to get a final concentration of 2 μg / 30 μl. To the diluted RNA 
samples, 13.9 μl of master mix* was added and the tubes were incubated at 420C for 1 hour 
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and 30 minutes on a thermal shaker. Upon completion of i cubation, cDNA samples were 
stored at -200C until used for RT-PCR analysis using SYBR green. The cDNA samples 
prepared as described above were diluted 1:10 for the real-time RT-PCR. 2 μl of diluted 
cDNA samples were mixed with SYBR green master mix (10 μl), forward primer (0.6 μl) and 
reverse primer (0.6 μl), that are specific for the gene of interest, Taq polymerase (0.16 μl) and 
distilled water (6.64 μl). The real-time RT-PCR was performed using Light Cycler480. 
*The master mix was prepared by mixing 9 μl of 5x buffer (Invitrogen, Karlsruhe, Germany), 
1 μl of 25 mM dNTP mixture (Amersham Pharmacia Biotech, Freiburg, Germany), 2 μl of 
0.1 M DTT (Invitrogen, Karlsruhe, Germany), 1 μl of 40U/ μl RNAsin (Promega, Mannheim, 
Germany), 0.5 μl of Hexanucleotide (Roche, Mannheim, Germany), 1 μl of Superscript 
(Invitrogen, Karlsruhe, Germany) or ddH2O in the case of the control cDNA (RT minus).  
 
3.11.5 Real time PCR 
SYBR Green Dye detection system (SYBR Green I 96 protocol LC480 Roche running 
program) was used for amplification. Quantitative real-time PCR was performed on Light 
Cycler 480 (Roche, Mannheim, Germany). Each amplification step included initiation phase 
95°C, annealing phase 60°C and amplification phase 72°C and was repeated 45 times. Gene-
specific primers (300 nM, Metabion, Martinsried, Germany) were used as listed in table 4. 
Controls consisting of ddH2O were negative for target and housekeeper genes. Primers were 
designed to be cDNA specific and to target possibly all known transcripts of genes of interest. 
In silico specificity screen (BLAST) was performed. The lengths of amplicons were between 
80 and 130 bp. The kinetics of the PCR amplification (efficiency) was calculated for every 
set of primers. The efficiency-corrected quantification was performed automatically by the 
LightCycler 480 based on extern standard curves describing the PCR efficiencies of the target 
and the reference gene [ratio = EtargetΔCPtarget (control − sample)/ErefΔCPref (control − 
sample)]. To reduce the risk of false positive Cp the high confidence algorithm was used. All 
the samples that during the amplification reaction did not rise above the background 
fluorescence (crossing point Cp or quantification cycle Cq) of 40 cycles were described as 
not detected (n.d. = not detected in the figures). Crossing points between 5 and 40 cycles 
were considered as detectable. The melting curves profiles were analyzed for every sample to 
detect unspecific products and primer dimers. Products were visualized on agarose gels, 
extracted and analyzed for sequence. 
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3.11.6 Oligonucleotide primers used for SYBR-Green RT-PCR 
The following oligonucleotide primers were used in this thesis. 
 
Table: 4. Oligonucleotide primer sequences used in the study 
Gene Sequence 
18s Forward: GCAATTATTCCCCATGAACG 
Reverse: AGGGCCTCACTAAACCATCC 
Ccl2 Forward: CCTGCTGTTCACAGTTGCC 
Reverse: ATTGGGATCATCTTGCTGGT 
Cxcl10 Forward: GGCTGGTCACCTTTCAGAAG 
Reverse: ATGGATGGACAGCAGAGAGC 
IL-6 Forward: TGATGCACTTGCAGAAAACA 
Reverse: ACCAGAGGAAATTTTCAATAGGC 
Nphs1 
(Nephrin) 
Forward: TTAGCAGACACGGACACAGG 
Reverse: CTCTTTCTACCGCCTCAACG 
Nphs2 
(Podocin) 
Forward: TGACGTTCCCTTTTTCCATC 
Reverse: CAGGAAGCAGATGTCCCAGT 
Nos2 
(iNos) 
Forward: TTCTGTGCTGTCCCAGTGAG 
Reverse: TGAAGAAAACCCCTTGTGCT 
Tnf-α Forward: CCACCACGCTCTTCTGTCTAC 
Reverse: AGGGTCTGGGCCATAGAACT 
Wt-1 Forward: CATCCCTCGTCTCCCATTTA 
 Reverse: TATCCGAGTTGGGGAAATCA 
CXCL2 Forward: CGGTCAAAAAGTTTGCCTTG 
 Reverse: TCCAGGTCAGTTAGCCTTGC 
CD44 Forward: AGCGGCAGGTTACATTCAAA 
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 Reverse: CAAGTTTGGTGGCACACAG 
BAD Forward: GTACGAACTGTGGCGACTCC 
 Reverse: GAGCAACATTCATCAGCAGG 
FGL-2 Forward: AGGGGTAACTCTGTAGGCCC 
 Reverse: GAACACATGCAGTCACAGCC 
BID Forward: GTGTAGCTCCAAGCACTGCC 
 Reverse: GCAAACCTTTGCCTTAGCC 
NOXA Forward: ACTTTGTCTCCAATCCTCCG 
 Reverse: GAAGTCGCAAAAGAGCAGGA 
PUMA Forward: CACCTAGTTGGGCTCCATTT 
 Reverse: ACCTCAACGCGCAGTACG 
 
3.12 Flow cytometry 
Flow cytometric analysis of cultured and renal immune cells was performed on a FACS 
Calibur flow cytometer (BD) as described 52. Every isolate was incubated with binding 
buffer containing either anti-mouse CD11c, CD11b, CD103, F4/80, and CD45 antibodies 
(BD) for 45 min at 40C in dark were used to detect renal mononuclear phagocyte 
populations. Anti-CD86 (BD) was used as activation marker. Anti-CD3 and CD4 (BD) were 
used to identify the respective T-cells population. 
 
3.13 In-vitro methods 
3.13.1 Cell freezing and thawing 
At earlier passages, large amounts of cells were grown under standard culture conditions and 
were frozen for future use. For freezing cells, cells were detached from the culture plates and 
spun down under sterile conditions for 3 minutes at 1000 rpm. The cell pellet was maintained 
on ice and carefully re-suspended in cold freezing medium (90 % FCS and 10 % DMSO) by 
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pipetting the suspension repeatedly up and down. 1.5 ml aliquots were quickly dispensed into 
freezing vials (40C) and the cells were slowly frozen at –200C for 1 hour and then at –800C 
overnight. The next day, all aliquots were transferred into liquid nitrogen. 
In order to thaw cells, a frozen vial was removed from liquid nitrogen and put into the water 
bath at 370C. The cells were then dispensed in 5 ml of warm coplete growth medium and 
spun down at 1000 rpm for 5-7 minutes. The old medium was then removed and the cells 
were re-suspended in fresh medium and transferred into a new culture plate. The medium was 
changed once more after 24 hours. 
3.13.2 Cell culture 
GEnCs were cultured using standard cell culture techniques. Briefly, cells were thawed from 
liquid nitrogen and immediately seeded into 150c m2 cell culture plates containing 20 ml of 
complete RPMI media with 10 % FCS and 1 % PS. Cells were allowed to grow until they 
became confluent, fresh media was supplied every 2 days. For growing podocytes and 
mPECs specified media was used, in which RPMI containi g 1 % P/S and 5 % FCS and if 
required for controlling pH we used 1% Sodium pyruvate, 1 % HEPES and 1 % Sodium 
Bicarbonate. When cells reached 80-90% confluence, they were split or detached from the 
plate by adding 2 ml of trypsin solution and the cells incubated at 370C for 2-3 minutes. Once 
the cells were detached from the plate, trypsin wasneutralized by adding complete media, 
and then the cells were centrifuged at 1200 rpm for 5 minutes. The cells were re-suspended in 
normal media and exact number of cells counted using a Neubauer chamber. The required 
number of cells was used for the different experiments like cytotoxicity assay using MTT 
dye, angiogenesis assay etc. 
 
3.13.3 Assessment of histone induced toxicity on GEnC 
For cytotoxicity experiments, 10 to 15x104 GEnCs were seeded in 96-well plates andallowed 
to adhere overnight. Once the cells adhered to the plat s, different concentrations of histones 
were added to the cells in the absence or presence of anti-histone IgG, whereas control groups 
were only stimulated with Control IgG for 18 to 24 hours. Cytotoxicity was detected by non-
radioactive cell proliferation assay kit. Briefly, after the stimulation cells were supplemented 
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with 15 µl of the MTT dye solution and incubated at 370C for 4-6 hours. During this time, 
live cells were converting the MTT dye into colored formazon crystals and these crystals 
were then dissolved using 100 µl of stop solution. The color change can be detected using a 
photometer at λ=570 nm. The color is directly proportional to the live cells. 
 
3.13.4 Podocyte culture and detachment assay 
Podocytes are terminally differentiated highly specialized cells with a complex cellular 
architecture. Podocytes do not have the ability 
to divide and multiply, therefore we used 
immortalized podocytes (from H-2Kb-tsA58 
mice) that were cultured in the presence of 
recombinant mouse IFN-γ (100 U/ml) at 330C 
in collagen-1 coated plates using DMEM media 
containing 1% of HEPEs, sodium bicarbonate 
and sodium pyruvate (to maintain the pH of the 
medium). The cells were trypsinized once they 
were 80% confluent. For the differentiation of 
podocytes, cells were grown in collagen-I 
coated plates at 370C without IFN-γ for 14 days 
and then used for experiments. For detachment 
assays, a specific number of podocytes were 
plated in 10 cm dishes and allowed to 
differentiate. These differentiated cells were 
stimulated with histones (100 µg/ml) for 24 
hours with or without anti-histone IgG. In the 
case, podocytes detach from the plate, it is a 
sign that these cells are dead. This was 
determined by counting the detached cells in the 
supernatants and the ratio was reported as live 
and detached cells (Figure 11). Further results 
were also confirmed by an MTT assay. Figure: 11. Schematic diagram showing the 
procedure employed to perform the podocyte 
detachment assay. 
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3.13.5 Neutrophil isolation and NETs formation and cytotoxicity assay 
Neutrophils were isolated from mouse the peripheral blood. Whole blood was collected into 
heparin tubes from the facial vein and mixed with 1,25% of high molecular weight dextran 
(molecular weight 450K-650K), and RBCs were allowed to settle at 40C. The upper clear 
yellowish leucocyte rich layer was separated and lysed for the remaining RBCs using 
hypnotic lysis (ddH2O) and tonicity was maintained by adding 0,15M KCl. Resultant 
leucocytes were enriched for neutrophils by gradient centrifugation with Biocoll solution 
(density of 0,177). As the neutrophils were very sensitive to the external stimuli, care was 
taken not to activate them by aggressive shaking and all the procedure were performed at 
40C. No glass material was used as neutrophils sticks o the glass surface.  
Once the pure neutrophils were isolated, suspended in plane RPMI media and then incubated 
at 370C in CO2 incubator for 30 minutes to rest, the NETosis experim nts were carried out. 
We hypothesized that NETs can kill endothelial cells, therefore we performed co-culture 
experiments with GEnC and neutrophils followed by in-situ NETs formation using TNF-α or 
PMA (known agonists for NETs formation, concentrations used did not have any direct 
killing effect on GEnC). The cytotoxicity of NETs was analyzed by MTT assay, in which 
only survived GEnC were able to convert the MTT salt. The results were confirmed by 
immuno-fluorescence staining and scanning electron microscopy (SEM).  
3.13.6 Intra-renal administration of histones 
To check the cytotoxic effect of histones on glomerular cells, histones were injected directly 
into the renal artery of WT and Tlr2/4 KO mice as illustrated in figure 12. One group of mice 
received histones after treating with anti-histone IgG, whereas the control mice were 
administered with Control IgG. In the case of Tlr2/4 KO mice, histones were only injected to 
check the cytotoxic effects compared to WT mice. After 24 hours, mice were sacrificed and 
kidneys fixed in formalin and taken for histological evaluation using PAS and fibrinogen 
staining to check the effect on glomerular cells and e dothelial cell damage. 
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Figure: 12. Histone injection into the renal artery, the abdominal aorta and the left renal artery was 
prepared and a microcannula was placed into the left renal artery (left) for histone injection. The 
puncture site was mounted with glue before closure of the wound (right)9. 
 
3.13.7 Isolation of glomeruli 
To further confirm the cytotoxic effects of histones on glomerular cells, we isolated pure 
glomeruli from WT and Tlr2/4 KO mice. The glomerular fraction was isolated by using 
magnetic isolation using perfusion of paramagnetic beads. Briefly, animal were anesthetized 
by an intraperitoneal injection of narcosis mix. Animals were cut open by midline incision 
and kidneys excised along with the intact arteries and veins and then taken for microsurgery 
using Leica, WILD M10 microscope with the help of micro scissors and forceps. Renal 
arteries were cut open to locate the arterial entrance into the kidney. Using a 1 ml syringe 
containing paramagnetic, beads were slowly administered into the kidney containing 2x106 
magnetic beads (Dnabeads, M-450 Epoxy). Successful perfusion will turn the kidney pale. 
After completion of the perfusion, kidneys were minced into fine pieces. Kidney samples 
were then digested with collagenase A for 30 minutes at 370C and the digested tissue was 
passed through a 100 µm cell strainer on ice. Digested and filtered tissue was passed though 
cell separation magnet (BD IMagnet, BD) and washed 5 times to isolate the glomeruli 
fractions. The first wash elutes the tubulointerstitial part of the kidney, the second wash 
eluted predominantly the tubular fraction and the remaining fractions were washed carefully 
until a 95 % to 98 % purity of glomeruli was obtained upon microscopic observation. The 
uniform glomeruli were seeded in 96-well plates and stimulated with histones to check the 
cytotoxic effects on the entire glomeruli, which can be measured by the release of LDH. The 
results were compared between WT and Tlr2/4 KO glomeruli. In another set of experiment, 
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following histone stimulation with or without α-Histone IgG for 6 hours all fractions were 
lysed using RNA lysis buffer to prepare mRNA and stored at -200C until further use. 
3.13.8 In-vitro tube formation assay 
To study the cytotoxic effects of histones on formed microvasculature, we setup the tube 
formation assay in which the cells were grown on 3D-matrix made of basement membrane 
protein called matrigel.  Matrigel was thawed overnight at 400C to make it liquid and 10 µl 
was added into each well of the µ-slide angiogenesis (ib di, Munich, Germany) allowing 
solidifying at 370C. GEnCs were seeded at 1x104 cells/well and stimulated with VEGF and b-
FGF as positive control or with histones in the absence or presence of histone antibody. Tube 
formation as a marker of angiogenesis was assessed by light microscopy by taking series of 
pictures at 0 hour, 4 hours, 8 hours and 24 hours. The cell covered area was calculated using 
the software photoshop. Angiogenic score was determin d by blinded technique. 
 
3.14 BWA3 hybridoma culture and anti-histone IgG purification 
Anti-histone IgG was isolated from the culture supernatants of monoclonal BWA-3 
hybridoma cells. Initially BWA-3 cells were revived from liquid nitrogen and cultured in 
normal growth medium (DMEM) containing 10 % FBS and 1 % PS until the cells attain 
confluence. Cells were collected by centrifugation a d seeded in CD hybridoma media 
containing 5 % ultra-low IgG serum, 1 % PS and 2 mM glutamine into cell culture flasks 
(Monestier et al, 1993). Cells were allowed to grow and during this time, hybridoma cells 
secreted α-Histone IgG in the supernatants. After 7-8 days, the supernatant was centrifuged to 
separate the cells and debris, and suspension was filter through 0.22 µm membranes and 
stored at 40C in SCOTH bottles. To purify and concentrate anti-histone IgG, hybridoma 
culture supernatants were passed through high trap protein GHP columns. Initially, columns 
were activated by passing 20 mM sodium phosphate buff r (pH 7.0) through followed by the 
hybridoma culture supernatant. During this process, antibodies bind to protein GHP columns 
and this can be eluted using low pH  (0,1M glycine hydrochloride buffer (pH 2,7)) into 2 mL 
Eppendorf tubes and the acidic pH can be neutralized to 7 using the appropriate amount of 
1M Tris-HCl buffer (pH 9,0). 
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The obtained antibody can be quantified for its concentration by measuring the absorbance 
(optical density O.D) using a UV-visible spectrophotometer at a wave length of 280 nm for 
total protein concentration. For determining the actu l concentration of the anti-histone IgG, 
the O.D values were multiplied with the factor 0.7 and the antibody was then stored at -200C 
until further use. Binding efficiency of the antibody was confirmed by western blotting using 
total histones as positive control.  
Note: avoid repeated freezing and thawing of anti-histone IgG 
 
3.15 Statistical analysis 
Data are presented as mean ± SEM. For multiple comparisons of groups one way ANOVA 
was used with post-hoc test using GraphPad prism (CA, USA). Paired Student`s t-test was 
used for the comparison of single groups. A value of p < 0.05 was considered to indicate 
statistical significance. 
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4. Results 
 
4.1. Glomerular expression of TLR2 and TLR4 in human severe glomerulonephritis 
Allam et.al have previously shown that extracellular histones can acts as ligands for TLR2 
and TLR4 leading to the tubular injury after AKI9. Therefore we studied the expression of 
these receptors in the glomeruli of both healthy and severe glomerulonephritis in human 
kidneys. To investigate this, we performed immunohistological staining using TLR2 and 
TLR4 antibodies in healthy human kidney (Biopsy taken during kidney transplantation) and 
kidney biopsies from patients with ANCA-vasculitis, a severe form of glomerulonephritis.  
TLR2/4 immunostaining of normal human kidney showed only a weak granular positivity in 
all glomerular cells, whereas TLR4 positivity was clearly observed in the glomerular 
endothelial cells (Figure 13A). In addition, TLR2 was strongly expressed in the cytoplasm of 
epithelial cells of the proximal and distal tubule, while the TLR4 expression was less 
prominent (Figure 13A).  
However, immunostaining of kidney biopsies from patients with ANCA-associated 
necrotizing and crescentic GN revealed a strong expression of TLR2 and TLR4 also in 
parietal epithelial cells (PECs) along the inner aspect of the Bowman`s capsule (Figure 13B). 
Furthermore, glomerular crescents are known to be predominantly formed by PECs171,172. As 
shown in Figure 13C, glomerular crescents were positive for both receptors TLR2 and TLR4, 
and the isotype IgG staining confirmed the specificity as this control staining was negative in 
all tissues (Figure 14). Together, TLR2 and TLR4 expr ssion was observed in the cells of the 
normal glomerulus and ligands for the TLR2/4 can activ te PECs proliferation and 
responsible for the induction of crescentic GN. 
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Figure: 13. TLR2 and TLR4 expression in human crescentic glomerulonephritis. Toll-like receptor 
(TLR)-2 and -4 immunostaining was performed on healt y kidney tissue (A) or on kidney biopsies 
from patients with recently diagnosed ANCA vasculitis and clinical signs of glomerulonephritis (B 
and C). (B) Glomeruli were unaffected by loop necrosis or crescent formation, while glomeruli 
affected by such lesions are shown in (C). Original m gnification x400. 
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Figure: 14. Isotype staining were negative in both control andANCA kidney sections. 
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4.2. Extracellular histones drive glomerular cell necrosis in-vitro 
4.2.1. Anti-histone IgG prevents histone toxicity on glomerular cells 
It has been previously reported that extracellular histones can cause toxicity and kill different 
types of cells including tubular epithelial cells and pulmonary endothelial cells in-vitro and 
in-vivo9. To confirm the cytotoxic effect of extracellular histones on cultured glomerular 
endothelial cells (GEnCs), we cultured GEnCs in 96 well plates at a cell density of 10.000 to 
15.000 cells/well in the presence of different concentration of histones and with or without 
the neutralizing histone antibody to block the action of histones. The cells were stimulated for 
24 hours and the OD measured via a photospectrometer at 570nm. As shown in Figure 15A, 
treatment of GEnCs with the histone preparation result d in a decrease in the absorbance 
(OD) indicating that histones were cytotoxic on GEnCs. This cytotoxic effect of histones on 
GEnCs occurred in a dose-dependent manner. Previously, anti-histone IgG derived from 
BWA3 hybridoma has been demonstrated to be able to neutralize the cytotoxic and 
immunstimulatory effect of extracellular histones10,94,141. To test this, GEnCs were incubated 
with anti-histone IgG (at 100µg/ml concentration) following treatment with different 
concentration of histones. The data show that anti-his one IgG almost entirely prevented 
histone toxicity in glomerular endothelial cells up to a histone concentration of 30μg/ml 
(Figure 15A).  
Next, we wanted to investigate whether histones had a cytotoxic effect on other glomerular 
cells such as PECs and podocytes. To do so, these cell  were cultured with different histone 
concentration in the absence or presence of anti-histone IgG. Histones also induced toxicity 
in cultured PECs and podocytes, but occurred at much higher histone concentrations (Figure 
15B and 15C) compared to the toxic dose required for killing endothelial cells (Figure 15A). 
Neutralization of histones with anti-histone IgG prevented the killing action of histones on 
PECs and podocytes in an efficient manner (Figure 15B and 15C). The findings confirmed 
the cytotoxic effects of histones on glomerular cells that were inhibited following treatment 
with anti-histone IgG. 
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                      A 
B  
C  
 
Figure: 15. (A) Murine glomerular endothelial cells (GEnC), (B) podocytes, and (C) parietal 
epithelial cells (PECs) were incubated with increasing doses of histones together with either control 
IgG or anti-histone IgG. Cell viability was determined after 24 hours by MTT assay. Values are the 
mean ± SEM of three independent experiments. * = P < 0.05, ** = P < 0.01, *** = P < 0.001. 
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4.2.2. Anti-histone IgG prevents histone toxicity on neovascularization and microtubules 
Endothelial cells have been shown to grow on matrigel surface, which resembles the 
microvasculature of the glomeruli. Therefore, this model seemed to be suitable to mimic the 
in-vivo conditions of glomerular capillary system and to sudy the cytotoxic effects of 
histones on the microvasculature. 
In our next in-vitro experiments, GEnCs were grown on a Matrigel surface to form 
neovascularization or microtubules, which resembles the microvasculature similar to that 
observed in the glomerular tuft. The addition of histones (40µg/ml) induced destruction of a 
microtubule formation within 12 hours, whereas treatment with anti-histone IgG prevented 
histone-induced GEnC microtubule destruction after 8 and 24 hours, as illustrated in Figure 
16A. Treatment of endothelial cells with anti-histone IgG resulted in an increase in the cell 
covered area (Figure 16B) and a significant high angiogenesis score (Figure 16C) compared 
to control IgG. 
 
Figure: 16. Histones and endothelial cell microtubes in vitro. (A) Murine glomerular endothelial cells 
were seeded into a matrigel matrix for angiogenesis xperiments as described in methods (section 
3.10.8 treated with histones, with or without anti-histone IgG. After 8 hours and 24 hours of 
stimulation, the control IgG group shows complete GEnC death, whereas the anti-histone IgG group 
shows a well preserved microvasculature. (B) Cell covered area and (C) angiogenic score are 
demonstrated. Values are the mean ± SEM of two independent experiments. ** = P < 0.01, *** = P < 
0.001. 
B 
 
 
 
 
C 
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Next, we allowed the formation of microtubules for 12 hours on a matrigel surface. After the 
microtubule formation was completed, we stimulated the microtubules with histone 
(40µg/ml) in the presence or absence of anti-histone IgG after 8 hours (as 0 hour control). 
The data in Figure 5 demonstrate that prior to the stimulation with histone both groups 
showed well-formed microtubules with the same percentage of cell covered area and 
angiogenesis score. After 12 hours of histone treatm n , the microtubule structure was 
destroyed in the control IgG groups (Figure 17A) and the percentage of the cell covered area 
and the angiogenesis score decreased (Figure 17B and 17C), which was completely rescued 
by treatment with anti-histone IgG. The data confirmed that histones also had the ability to 
kill already formed microtubules, which is most likely to occur in in-vivo settings as well. 
Therefore, neutralization of histones was beneficial to protect the microvasculature.  
 
 
 
Figure: 17. Histones and endothelial cell microtubes in-vitro. (A) Murine glomerular endothelial cells 
were seeded into a matrigel matrix for angiogenesis xperiments as described in methods (section 
3.10.8) treated with histones, in the presence or absence of anti-histone IgG. After 0 hour and 12 
hours of stimulation, control IgG showed GEnC death, w ereas treatment with anti-histone IgG 
preserved the microvasculature. (B) The percentage of cell covered area and (C) angiogenic score. 
Values are the mean ± SEM of two independent experiments. * = P < 0.05, *** = P < 0.001. 
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4.3. Neutrophil extracellular traps kill glomerular endothelial cells through histone 
release 
4.3.1. Histones were released during NETosis  
Previously, it has been reported that during severe GN neutrophils can undergo NETosis173.  
NETosis is a form of programmed cell death that occurs in the presence of cytokines released 
from dying cells due to a severe inflammatory insult160,174. As a consequence nuclear 
chromatin including histones and DNA are released from NETting neutrophils within the 
glomerular capillaries25. We hypothesized that histones present within the chromatin structure 
were functionally pathogenic during GN. To investiga e this in more detail, we performed in-
vitro experiments to demonstrate the formation of NETs from isolated neutrophils. 
Neutrophils were stimulated or left untreated for 8 hours and then stained for elastase (red) 
and histones (green). Fluorescent microscopy showed that PMA-activated neutrophils 
released chromatin material including histones compared to unstimulated cells (Figure 18) 
indicating that activated neutrophils were forming NETs and released their nuclear material 
including histones. 
 
 
Figure: 18. Non-activated neutrophils did not form NETs (left image). Right image, neutrophils 
formed NETs following activation with PMA and released nuclear material including the granular 
protein elastase (red) and the nuclear proteins histone  (green) into the extracellular space. 
 
Elastase + Histones
Non-activated neutrophils                    Activated neutrophils forming NETs
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4.3.2. Histones in the formed NETs kill GEnC in-vitro 
To further investigate the killing action of histones, we set up an experiment where we added 
neutrophils onto a monolayer of GEnCs and incubated th  cells in the presence of TNF-α or 
PMA in 4 well permonax microslides to induce NETosis. The killing action of NET related 
histones was evaluated by scanning electron microscopy (SEM). After inducing NETs on a 
monolayer of GEnC using TNF-α in the absence of presence of anti-histone IgG, the cells 
were fixed using electron microscopic fixative (2 % glutaraldehyde and 2 % 
paraformaldehyde) and analyzed for the pathogenic changes induced by NETs on GEnC. The 
SEM results showed that TNF-α treatment alone did not affect the morphology of GEnC 
(Figure 19, left). However, TNF-α activated neutrophils formed NETs that killed the 
monolayer of GEnC as illustrated by blebs formation on the cell surface (Figure 19, middle). 
In the group where anti-histone IgG was added to the cells, the GEnC were completely 
protected from the cytotoxic effects exhibited by the NETs (Figure 19, right), whereby the 
GEnC showed normal cell morphological features similar to the control group (Figure 19, 
left). 
 
 
Figure: 19. Scanning electron microscopy was performed on monolayers of glomerular endothelial 
cells, which appeared flat and evenly laid out (left image). However, neutrophil ETosis caused severe 
injury and death of endothelial cells appearing as bulging white balls with corrugated surfaces 
adjacent to TNFα-activated NETs (middle image). This effect was almost entirely prevented by anti-
histone IgG treatment demonstrated by a significant reversal of the structural integrity of the 
endothelial cell monolayer (right image). 
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The killing actions of NETs-related histones were further investigated by immunostaining of 
fixed cells. The data showed that neutrophils that were undergoing TNF-α induced NETosis 
destroyed the monolayer of glomerular endothelial cells by inducing endothelial cell death, 
which can be seen by reduced DAPI staining (Figure 8A, middle) compared to treatment with 
TNF-α alone (Figures 20A, left). Interestingly, the observed NETosis-related endothelial cell 
toxicity was entirely prevented by anti-histone IgG treatment (Figure 20A, right) that did not 
affect NET formation as illustrated by clumping of elastase (red) and histones (green) and 
preserved DAPI staining (blue). Together, we conclude that NETting neutrophils damage 
glomerular endothelial cells via the release of histones. These findings were confirmed using 
a colorimetric MTT assay to measure endothelial cell viability. As shown in Figure 20B, 
addition of anti-histone IgG resulted in a significant increase in the O.D values compared to 
the control IgG-treated group when neutrophils were stimulated with the NETosis inducing 
stimuli TNF-α or PMA indicating that anti-histone IgG prevented death of GEnC. Non-
activated neutrophils did not induce GEnC death that was independent of anti-histone IgG 
treatment. 
 
Figure: 20. Anti-histone IgG prevents cell death in glomerular endothelial cells. Glomerular 
endothelial cells were co-cultured with TNF-α-activated neutrophils in the presence of anti-histone 
IgG or control IgG. (A) Immunostaining for elastase, histone, and DAPI. (B) Neutrophils were 
activated with the NETosis stimulus TNF-α and PMA and the MTT assay analysis of endothelial cell 
viability was used to measure the O.D at 570 nm. Values are the mean ± SEM of two independent 
experiments. ** = P < 0.01. 
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4.4. Histones need TLR2/4 to trigger glomerular necrosis and microangiopathy  
Allam R et al has previously reported that extracellular histones mediate its cytotoxic effects 
in a TLR2/4-dependent manner in tubular epithelial cel s9. Currently, it is unknown whether 
glomerular toxicity of extracellular histones occurs in a TLR2/4-dependent manner. To 
answer this question we have setup ex-vivo and in-vivo experiments using glomeruli that were 
isolated from Tlr2/4-deficient mice. 
4.4.1.  Histones are cytotoxic to wild-type but not Tlr2/4-deficient glomeruli ex-vivo 
To determine the cytotoxic effect of extracellular histones, we isolated glomeruli from wild-
type (Figure 21, picture) and Tlr2/4-deficient mice and incubated the glomeruli with histones 
at a concentration of 50 μg/ml ex-vivo for 12 hours. Following incubation, we performed a 
lactate dehydrogenase (LDH) assay to measure the cyotoxic effect of extracellular histones. 
We found that histone exposure of glomeruli isolated from wt mice resulted in a significant 
increase in the LDH levels confirming the cytotoxicity of histones on glomeruli (Figure 21, 
graph). Interestingly, the LDH levels were significantly reduced when glomeruli from Tlr2/4-
deficient mice were treated with histones compared to glomeruli from wt mice (white bars). 
This indicated that the cytotoxic effect of extracellular histones on glomeruli occurred in a 
TLR2/4 dependent manner.  
 
 
 
 
 
 
 
 
Figure: 21. (Left image) Representitive image of isolated glomeruli from wild-type (wt) mice. (Right 
graph) Glomeruli were isolated from wt and Tlr2/4-deficient mice and incubated ex-vivo with histones 
(30 µg/ml). After 12 hours, LDH release in the supernatants was measured as a marker of glomerular 
Results                                                                                                                                    65 
cell injury. Data represent mean OD ± SEM of three experiments measured at a wavelength of 492 
nm. ** = P < 0.01, *** = P < 0.001. 
4.4.2. Extracellular histones stimulate inflammation in wild-type glomeruli ex-vivo 
After showing that extracellular histones were cytotoxic to glomeruli isolated from wt mice, 
we wanted to investigate the pro-inflammatory effects of extracellular histones. Therefore, 
we exposed glomeruli that were isolated from both wt and Tlr2/4-deficient mice with 
histones (50 µg/ml) and measured the mRNA values of pro-inflammatory cytokines via real 
time RT-PCR. As shown in Figure 10, glomeruli isolated from wt mice that were stimulated 
with histones significantly increased the mRNA expression of pro-inflammatory mediators 
such as TNFα (Figure 22A) and IL-6 (Figure 22B). In contrast, glomeruli from Tlr2/4-
deficient mice, when exposed to histones, did not trigger the expression of IL-6 and TNF 
mRNA indicating that the pro-inflammatory effect of histones also occurred in a TLR2/4-
dependent manner (Figure 22A and 22B). 
 
Figure: 22. Induction of cytokines in isolated glomeruli ex-vivo that were exposed to histones. 
Glomeruli were isolated from wild type (wt) and Tlr2-/4 double knockout mice, and exposed to 
histones (50μg/ml). After 12 hours, the mRNA levels of TNF-α (A) and IL-6 (B) were determined by 
real-time RT-PCR. Values are the mean ± SEM of two independent experiments. * = P < 0.05, ** = P 
< 0.01. 
 
4.4.3. Extracellular histones need involvement of TLR2/4 to show its toxic effects in-vivo 
Finally, we wanted to look at the toxic effect of histones on glomeruli in-vivo. Reports have 
previously shown that an intravenous injection of histones can cause pulmonary 
microvascular injury, which is lethal in mice10. Therefore, we injected histones 10 mg/kg 
directly into the left renal artery in both wt and Tlr2/4-deficient mice that were anesthetized. 
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After 24 hours, kidneys were harvested and photon microscopy carried out to look at the 
structures of glomeruli. As shown in Figure 23A, treatment of histones in-vivo destroyed the 
structure of glomeruli (glomerular lesions) in wt mice that was well preserved in Tlr2/4-
deficient mice. Unilateral histone injection caused glomerular lesions in wt mice that showed 
characteristics of minor endothelial fibrinogen positivity (Figure 23B), capillary obstruction 
and thrombotic microangiopathy (Figure 23C) and globa  glomerular necrosis (Figures 23D). 
Histone injection into the renal artery of Tlr2/4-deficient mice caused not only reduced 
glomerular lesions but also significantly less fibrinogen positivity (endothelial positivity, 
capillary obstruction and loop necrosis), as demonstrated in Figures 23E. These in-vivo 
results confirmed that extracellular histones induce glomerular injury occurs in a TLR2/4-
dependent manner. 
 
Figure: 23. (A) For intra-arterial histone injection the abdominal aorta was prepared and a micro-
cannula was placed into the left renal artery to inject histones directly into the kidney. Images show 
hematoxylin-eosin staining of isolated glomeruli from saline and histone-treated wt mice as well as 
from histone-treated Tlr2/4-deficient mice. (B-D) Fibrinogen immunostaining of glomeruli isolated 
from wt mice displaying three different staining patterns: diffuse positivity of glomerular endothelial 
cells, entire luminal positivity indicating microthrombus formation, and global positivity of 
glomerular loop indicating loop necrosis. Original magnification x400. (E) Quantitative analysis of 
these lesions (glomeruli injury score). Values are the mean ± SEM of two independent experiments. 
** = P < 0.01, *** = P < 0.001. 
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4.5. Extracellular histones contribute to severe glomerulonephritis 
4.5.1. Inhibition of NETs using Cl-amide in-vivo prevents glomerulonephritis 
We hypothesized that extracellular histones released from NETs may also play an important 
role during the progression of severe GN173. To address our theory, we blocked NET 
formation by using the peptidylarginine deiminase (PAD) inhibitor102,175,176 Cl-amide at the 
dose of 10mg/kg in an in-vivo model of severe GN. Mice were injected with heterolog us 
sheep anti-rat GBM serum (100µl per mouse) to induce severe GN prior to a daily 
intraperitoneal (i.p.) injection of the PAD inhibitor (Cl-amide in 25 % DMSO). Control mice 
received only vehicle (25 % DMSO). After 7 days, mice were sacrificed and the glomeruli 
lesions of the treated kidneys analyzed for extracellular myeloperoxidase (MPO) and CD31 
expression. As shown in Figure 12, treatment with the PAD inhibitor Cl-amidine prevented 
glomerular NET formation as evidenced by reduced MPO immunostaining (red) and 
quantitative measurement of the fluorescence area. In contrast, the blockade of glomerular 
NET formation preserved glomerular CD31+ endothelial cells, as demonstrated by a 
significant increase in the fluorescence intensity (Figure 24, green) and the fluorescent area 
(graph).  
 
 
 
 
 
 
 
Figure: 24. (A) CD31 (green) and myeloperoxidase (MPO) (red) immumostaining representing NETs 
formation in the glomeruli in close association with the endothelial cells, vehicle group shows focal 
loss of endothelial cell positivity compare to treament with the PAD inhibitor (PAD.inh). (B) 
Quantification of mean fluorescence area for MPO and CD31 positivity in glomeruli. 
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The previous data have shown the protective effect of the PAD inhibitor Cl-amide leading to 
a preserved endothelial microvasculature in the glomeruli during anti-GBM induced GN. We 
further measured the proteinuria in terms of the albumin to creatinine (A/C) ratio by ELISA. 
The results demonstrated that Cl-amide treatment significantly reduced the A/C ratio 
compare to the vehicle group (Figure 25A). This was al o the case for the functional 
parameter including BUN levels (Figure 25B). Within this thesis we have shown that the 
main cause of proteinuria in the necrotizing GN model was due to the loss of podocytes 
within the glomeruli. Here, we wanted to evaluated his in more detail on histological 
sections using immunostaining of nephrin and WT-1 positive podocytes. Following Cl-amide 
treatment, we found a normal or maintained number of podocytes compare to the vehicle 
group (Figure 25C). PAS staining of sections were analyzed for glomerular morphology in 
healthy, segmental and global lesions in glomeruli. The results showed that Cl-amide 
treatment significantly increased the number of normal glomeruli and significantly decreased 
the global sclerotic lesions compare to the vehicle group (Figure 25D). Furthermore, one 
characteristic features of necrotizing GN are vibrant crescentic glomeruli that were 
significantly reduced upon Cl-amide treatment in comparison to the vehicle group (Figure 
25E).  
The infiltration of inflammatory cell represents another complication of necrotizing GN. To 
look at the infiltration of inflammatory cells in the glomeruli, we used immunostaining to 
identify Mac-2+ macrophages. The data showed that Cl-amide treatment significantly 
reduced the number of infiltrating macrophages in the glomeruli compare to the vehicle 
group (Figure 25F). These findings were further confirmed by flow cytometry analysis of 
single cell kidney suspension using a combination of fluorescent surface antibodies. The 
obtained results demonstrated that treatment with the PAD inhibitor significantly reduced the 
number of activated inflammatory cells including CD11c+ MHCII+ double positive dendritic 
cells, F4/80+ MHCII+ positive macrophages and total CD11c+ CD11b+ cells and CD3+ CD4- 
CD8- T cells in the kidney (Figure 25G). These findings indicated that blocking NETosis 
using the PAD inhibitor Cl-amide during a necrotizing form of GN not only protected the 
endothelial microvasculature but also abrogated thekey features of GN including 
inflammatory cell recruitment. 
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Figure: 25. In an in-vivo model of antiserum-induced GN, treatment with the Cl-amide (PAD.inh) 
following antiserum injection attenuated the disease burden. (A and B) Levels of proteinurea (A) and 
BUN (B) measured in the urine on day 7. (C) Podocytes were quantified as nephrin/WT-1+ cells on 
renal sections on day 7. (D and E) PAS staining to determine the percentage of glomeruli (D) and  
crescentic glomeruli (E). (F) Number of Macrophages p r glomeruli determined by immunostaining 
using a Mac-2 antibody. (G) Flow cytometry analysis of kidney suspension. Data represent mean ± 
SEM from five to six mice per group. * = P < 0.05, ** = P < 0.01, *** = P < 0.001. 
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4.5.2. Anti-Histone IgG treatment prevents complication of GN 
We have previously shown that anti-histone IgG treatm nt can prevent the cytotoxic effect of 
histones on glomeruli in-vitro. To test whether these findings can be translated into an in-vivo 
model of GN, first we injected mice intravenously with 100 µl GBM antiserum that was 
either raised in sheep or in mice to induce necrotizing types of GN. After 7 days, histology 
staining showed that only sheep IgG deposits were found in the glomeruli but not mouse IgG 
(Figure 26) demonstrating that excess autologous anti-sheep IgG did not stimulate the 
immune response to induce its own effect in the progression of GN. Furthermore, in these 
experiments we excluded possible non-specific actions of sheep-IgG and have shown that the 
disease pathology is mainly caused by direct killing or necrotizing action of sheep anti-GBM 
serum on different glomerular cells leading to the pathological conditions without any 
autoimmune or autologous reaction against the sheep antiserum during the disease.    
 
 
Figure: 26. Day 7 after injection of anti-GBM serum the kidneys were positively stained for sheep 
IgG, whereas mouse IgG was negative excluding the autologous sheep IgG response. 
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Next, mice were injected i.p. with 20 mg/kg anti-histone IgG or with 20 mg/kg control IgG 
24 hours prior (prophylactic treatment) to the intravenous injection of 100 µl GBM antiserum 
that was raised in sheep. The treatment with anti-his one IgG or control IgG was continued on 
alternative days up to 7 days after sheep GBM antiserum injection. During the experiment, 
urine and blood was collected to analyze functional parameters. After 7 days of antiserum 
injection, mice were sacrificed and kidneys removed for histology, FACS and qRT-PCR 
analysis. As shown in Figure 27A, treatment with anti-histone IgG significantly reduced the 
BUN levels following GBM antiserum injections compared to the control IgG treatment 
group. Anti-histone IgG not only increased the number of healthy glomeruli but also 
significantly reduced the percentage of global glomeruli as demonstrated by PAS histological 
staining of sections (Figure 27B-27C). The decrease in the severity of GN following anti-
histone IgG treatment was further confirmed by the significant reduction in the percentage of 
crescentic glomeruli with less severe lesions on 7 days after antiserum injection in 
comparison to the control IgG treated group (Figure 27D).  
To investigate the effect of NET related histone blockade by the anti-histone IgG treatment, 
histological sections were stained for NET-related MPO staining and endothelial CD31 
markers to look at the effect on the maintenance of glomerular microvasculature. A focal loss 
of endothelial CD31 positivity, a marker of glomerular vascular injury, was observed in 
glomeruli isolated from control IgG treated mice (Figure 27E). However, anti-histone IgG did 
not affect extracellular positivity of MPO but maintained CD31+ vasculature indicating a 
protective effect on NET-related vascular injury. These results were further strengthened by 
quantifying the area of MPO+ and CD31+ showing that anti-histone IgG significantly 
increased the number of CD31 positivity compared to control IgG, whereas the MPO 
positivity remained unaffected (Figure 27F). Consistent with our in-vitro data, the in-vivo 
data now showed that anti-histone IgG treatment prevent d the disease pathogenesis of sheep 
GBM antiserum-induced severe GN and clearly implied the importance of anti-histone IgG 
regarding the maintenance of the glomerular microvasculature and the number of podocytes 
present within the glomeruli.  
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Figure: 27. Neutralizing of histones protects severe GN. (A) Blood urea nitrogen (BUN) levels were 
determined 1 and 7 days after intravenous injection of GBM antiserum. Mice were either treated with 
control IgG or anti-histone IgG prior to the injection with antiserum. (B) Representative HE staining 
of glomeruli are shown at an original magnification f 400x. (C and D) Morphometrical analysis of 
segmental and global glomerular lesions (left) and of glomeruli with crescents (right) as described in 
methods (section 3.8.1). (E) CD31 and MPO immunostaining representing NETs formation in the 
glomeruli close association with the endothelial cels, control IgG group shows focal loss of 
endothelial cell positivity compare to anti-histone IgG group. (F) Quantification of the mean 
fluorescence area for MPO and CD31 positivity in glomeruli. Data are means ± SEM from five to six 
mice in each group. * = P < 0.05, ** = P < 0.01, *** = P < 0.001 versus control IgG. 
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4.5.3. Neutralizing histones protects the glomerular filtration barrier in glomerulonephritis 
Because histones were shown to be toxic in glomerular endothelial cells and podocytes in-
vitro, we assessed the effect of anti-histone IgG treatmnt on the glomerular capillary 
ultrastructure during severe GN in-vivo via transmission electron microscopy. As illustrated 
in Figure 28, mice that received only control IgG treatment showed severe glomerular 
damage with fibrin deposits replacing large glomerular segments (fibrinoid necrosis). The 
capillary loops showed extensive GBM splitting and thinning, prominent endothelial cell 
nuclei, massive subendothelial edema with closure of the endothelial fenestrae, and 
obliteration of the capillary lumina (Figure 28, upper panel, left). Subendothelial transudates 
(leaked serum proteins) and luminal platelets and neutrophils were also noted (Figure 28, 
upper panel, right). Severe podocyte injury with diffuse foot process effacement, reactive 
cytoplasmic changes and detachment from the GBM were apparent (Figure 28, both pictures 
upper panel).  In contrast, glomeruli from mice injected with anti-histone IgG showed 
restored endothelial fenestrations, flat appearing e dothelial cells and preserved podocytes 
with intact foot processes (Figure 28, lower panel). 
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Figure: 28. Transmission electron microscopy of antiserum-induced GN revealed extensive 
glomerular injury with fibrinoid necrosis (upper left), endothelial cell swelling, luminal thrombosis, 
and intraluminal granulocytes (upper middle and right). Podocytes show foot process effacement (all 
upper images). Pre-emptive treatment with anti-histone IgG decreased most of these abnormalities in 
particular the endothelial cell and podocyte ultrastructure (lower images). 
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4.5.4.  Anti-Histone IgG treatment maintains podocytes intact 
A hallmark of glomerular diseases is an increase in proteinuria. This is mainly due to the loss 
of podocytes. To further investigate the cytotoxic effect of histones on in-vitro cultured 
podocytes, we stimulated the cultured monolayer of differentiated podocytes with histones in 
the absence or presence of anti-histone IgG. After 24 hours, we measured the detached 
podocytes by counting the floating (detached) podocytes manually in the culture 
supernatants. We found that addition of histones wa le ding to a significant increase in the 
percentage of detached podocytes in the control IgG group (Figure 29, black bars). In the 
presence of anti-histone IgG, the percentage of detach d podocytes significantly decreased 
indicating the killing action of histones on cultured podocytes (Figure 29, white bars). 
 
 
 
 
 
 
 
 
Figure: 29. Anti-histone IgG and podocyte detachment in-vitro. Murine podocytes were exposed to 
histones with or without anti-histone IgG. Data show the mean percentage ± SEM of podocytes that 
were detached from the culture dish within 24 hours. *** = P < 0.001 versus control IgG.  
 
Next, to confirm the effect of histone neutralization on podocyte counts in our in-vivo 
antiserum-induced GN model, we have used a co-immunostaining of WT-1 and nephrine to 
locate the podocytes in the glomerular turf. WT-1 (red) and nephrin (green) co-
immunostaining revealed that anti-histone IgG largely prevented podocyte loss in antiserum-
induced GN (Figure 30A), which was consistent with an increased number of WT-1/nephrin+ 
podocytes compared to control IgG (Figure 30B). On day 7, we also noticed a significant 
reduction of the albuminuria following injection with anti-histone IgG in GBM antiserum-
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treated mice, which was not observed on day 1 (Figure 30C). These results demonstrated that 
extracellular histones induced severe GN by causing glomerular vascular injury and podocyte 
loss. Furthermore, anti-histone IgG also showed a significant decrease in the proteinuria 
compare to the control group, which further confirms the maintenance of podocytes and 
endothelial barriers in anti-histone IgG treated mice.  
 
 
 
Figures: 30. (A) Immunostaining for WT-1 (red) and nephrin (green) was used to quantify podocytes. 
(B) The number of nephrin/WT-1+ podocytes following anti-histone IgG treatment on day 7 during 
antiserum-induced GN. (C) Urinary albumin/creatinine ratio was determined on day 1 and day 7 after 
antiserum injection. Data represent mean ± SEM from five to six mice per group. * = P < 0.05, *** = 
P < 0.001 versus control IgG. 
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We further analyzed the urinary albumin/creatinine ratios and the number of podocytes by 
immunostaining for nephrin and WT-1 in PAD inhibitor-treated mice. The blockade of 
NETosis using the PAD inhibitor resulted in a decrease in the albumin/creatinine ratio but in 
an increase in the number of podocytes similar to that observed with anti-histone IgG (Figure 
31A and 31B) 
 
Figure: 31. (A) Urinary albumin/creatinine ratio and (B) number of podocytes after blocking NETs 
with the PAD inhibitor. Data represent mean ± SEM from five to six mice of each group. * = P < 
0.05, *** = P < 0.001 versus vehicle group. 
 
4.5.5. Extracellular histones drive glomerular leukocyte recruitment and activation 
Infiltrating leukocytes are a key source of extracellular histones during severe GN25 and exert 
important effector functions including the production of chemokines during the pathogenesis 
of GN177. One such chemokine is Chemokine (C-X-C motif) ligand 2 (CXCL2), a small 
molecule belonging to the CXC chemokine family that is also known as macrophage 
inflammatory protein-2 (MIP-2). CXCL2 is mainly secr ted by monocytes and macrophages, 
and functions as a chemoattractant for polymorph nuclear leukocytes (neutrophils) and 
hematopoietic stem cells178-180. To investigate whether GEnC also express CXCL2, cultured 
GEnC were stimulated in-vitro with GBM antiserum at a concentration of 30µl/ml for 6 
hours and mRNA isolated from those samples were analyzed for the expression of CXCL-2 
by qRT-PCR. The results showed that stimulation of gl merular endothelial cells with GBM 
antiserum triggered the expression of CXCL2 (Figure 32) indicating that CXCL2 may well 
be the major chemokine for neutrophil infiltration into the glomeruli and further pathogenic 
effects.  
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Figure: 32. CXCL2 mRNA expression in glomerular endothelial cells. Exposure of GEnC to 
glomerular basement membrane (GBM) antiserum (30μl/ml) induced the expression of MIP-
2/CXCL2 mRNA, as determined by qRT-PCR. Data are the mean ± SEM from three independent 
experiments. ** = P < 0.01 (Student’s t-test). 
 
Finally, we investigated the effect of leukocyte infiltration in the in-vivo setting of severe GN. 
Immunostaining and manually counting of the number of neutrophils and macrophages per 
glomeruli showed that anti-histone IgG treatment in-vivo significantly reduced the numbers 
of glomerular neutrophils (Ly-6B.2) and macrophages (Mac-2) during severe GN (Figure 
33A). Furthermore, flow cytometry analysis of renal ce l suspensions was used to unravel the 
distinct renal mononuclear phagocyte populations during severe GN. As shown in Figure 
33B, we have identified 5 distinct cell populations, whereby the F4/80+ cells, F4/80+ 
MHCII+ cells and CD11b+ CD103+ cells were predominantly present in the kidney. Upon 
treatment with anti-histone IgG, the number of all cell populations was significantly reduced 
(Figure 33B).  
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Figure: 33. Leukocyte recruitment and activation during glomerulonephritis. (A) Glomerular 
neutrophil (Ly-6B.2) and macrophage (Mac-2) infiltrates were quantified by immunostaining. 
Representative images are shown at an original magnification of 400x. (B) Leukocyte activation was 
quantified by flow cytometry of renal cell suspensions harvested 7 days after antiserum injection. 
Data represent mean ± SEM from five to six mice of ach group. * = P < 0.05, ** = P < 0.01, *** = P 
< 0.001. 
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In an in-vitro experiment we also showed that histones are able to induce the upregulation of 
activation markers such as MHCII, CD40, CD80, and CD86 in cultured bone marrow-derived 
dendritic cells (BMDCs) in a dose-dependent manner that were significantly reduced 
following anti-histone IgG administration (Figure 34). Taken together, the in-vitro and in-
vivo data in this section demonstrated that extracellular histones triggered glomerular 
leukocyte recruitment and activation that can be blocked with anti-histone IgG. 
 
 
Figure: 34. Cultured bone marrow-derived dendritic cells were xposed to increasing doses of 
histones as indicated. After 24 hours, flow cytometry was used to determine the percentage of cells 
that expressed the activation markers MHCII, CD40, CD80 and CD86. Data are means ± SEM from 
three independent experiments. * = P < 0.05, ** = P < 0.01, *** = P < 0.001. 
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4.5.6. Extracellular histones trigger intraglomerular TNF-α release and thrombosis 
Activated mononuclear phagocytes have been shown to be an important source of pro-
inflammatory cytokine production during glomerular disease. Among these, TNF-α 
particularly contributes to the loss of podocytes, proteinuria, and glomerulosclerosis181. To 
investigate whether histones can trigger the production of TNF-α in mononuclear phagocytes, 
we cultured J774 macrophages and bone marrow derive dendritic cells (BMDCs) in the 
presence of different concentrations of histones in-vitro and measured the secreted level of 
TNF-α via ELISA. As shown in Figure 35A, histone-stimulated J774 macrophages and 
BMDCs produced TNF-α that was completely inhibited following addition of anti-histone 
IgG. We next assessed the glomerular TNF-α expression in-vivo on day 7 after antiserum 
injection. Immunostaining displayed a robust TNF-α positivity within the glomerular tuft that 
was not only expressed by the infiltrating cells but also present in the inner and outer aspect 
of the glomerular capillaries (Figure 35B). Interestingly, anti-histone IgG treatment 
significantly reduced the glomerular TNF-α positivity, which was consistent with the 
corresponding renal mRNA expression levels (Figure 35C). TNF-α is not only an inducer of 
NETosis but can also trigger the prothrombotic activity of (glomerular) endothelial cells and 
intravascular fibrin formation182-184. In our GN model, the glomerular capillaries were 
expressing global fibrinogen that was significantly decreased with anti-histone IgG (Figure 
35D). This was also the case for the fibrinogen mRNA levels in the presence of anti-histone 
IgG (Figure 35E). These results highlighted the importance of extracellular histones in 
triggering intraglomerular TNF-α production and microthrombi formation within the 
glomerular capillaries. 
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Figure: 35. Histones activate TNF-α production. (A) J774 macrophages and bone marrow dendritic 
cells (BMDCs) were cultured in the presence of different concentrations of histones with or without 
anti-histone IgG and secreted TNF-α levels determined by ELISA. Data are means ± SEM from three 
independent experiments. *** = P < 0.001 by two-way ANOVA with Bonferroni’s post test. (B and 
D) TNF-α and fibrinogen immunostaining on renal sections from both treatment groups taken on day 
7 after antiserum injection. Representative images ar  shown at an original magnification of 400x. (C 
and E): Real time RT-PCR for TNF-α and fibrinogen mRNA on renal tissue on day 7 after antiserum 
injection. Data are means ± SEM from at least five to six mice in each group. * = P < 0.05. 
 
 
 
 
 
Histones (µg/ml)
T
N
F
-α
 (
p
g
/m
l)
Media 10 20 30 40 50 100
0
50
100
150
200
Cont. IgG
α-Hist. IgG
***
Macrophages
Histones (µg/ml)
Media 10 20 30 40 50
0
200
400
600
BMDCs
   
 F
ib
ri
n
o
g
e
n
   
   
   
   
   
   
   
   
   
   
  T
N
F
-α
Cont. IgG α-Hist. IgG
A
B     C
D      E
F G
*** ***
***
***
***
***
*** ***
*** ***
T
N
F
-a
m
R
N
A
/1
8
s
rR
N
A
0
5 10- 0 6
1 10
- 0 5
1 10- 0 5
Cont. IgG α-Hist. IgG
*
F
ib
ri
n
o
g
e
n
 (
F
G
L-
2
)
m
R
N
A
/1
8
s
rR
N
A
0
1 10- 0 4
2 10- 0 4
3 10- 0 4
4 10- 0 4
5 10- 0 4
Cont. IgG α-Hist. IgG
*
Results                                                                                                                                    83 
4.5.7. Extracellular histones activate parietal epithelial cel s via TLR2/4 
Mitogenic plasma proteins that are leaking from the injured glomerular capillaries can cause 
PEC hyperplasia and glomerular crescent formation171,172,185. To investigate whether released 
DAMPs and leaked serum proteins as a result of endothelial damage and during the GN are 
responsible for the activation of PECs and crescent formation, PECs were first fluorescently 
stained with claudin-1 and the activation marker WT-1. As shown in Figure 36A, PECs were 
identified as claudin-1/WT-1 positive during antiserum-induced GN glomerular 
crescents186,187. However, in the presence of anti-histone IgG, PECs were less positive for 
WT-1 indicating that histones can induce the activation of PECs. Secondly, we performed in-
vitro experiments, where cultured and fully differentiated PECs were stimulated with a low 
dose of histones (20µg/ml) in the presence of different concentration of serum. The data 
showed that PECs significantly increased their proliferative capacity when treated with 
histones in the presence of different concentrations f serum (Figure 36B) that was 
significantly abolished following addition of anti-h stone IgG or anti-TLR2/4 antibodies 
(Figure 36C). Thirdly, the blockade of TLR2/4 reduced histone-induced mRNA expression of 
activation markers like CD44 and WT-1 in PECs (Figure 36D). Besides the effect of anti-
histone IgG and anti-TLR2/4 antibodies to block the toxic effect of extracellular histone, the 
same capability was attributed to heparin and recombinant activated protein C (aPC) 10,140. As 
such, the protective effect on PEC activation was confirmed by heparin, activated protein C 
(aPC), anti-TLR2/4 as well as anti-histone IgG treatment (Figure 36D).  
Finally, heparin and aPC were shown to be able to suppress the cytotoxic actions of histones 
on glomerular endothelial cells in the same way like anti-histone IgG did (Figure 37A-37B). 
Thus, extracellular histones can activate PECs in a TLR2/4-dependent manner, a process that 
may act synergistically with other triggers of PEC hyperplasia during crescent formation and 
that can be blocked by anti-histone IgG, aPC or heparin. 
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Figures: 36. (A) Renal sections were stained with claudin-1 (red, marker for parietal epithelial 
cells/PECs and some tubular cells), WT-1 (green, marker for podocytes and activated PECs), and 
DAPI (blue, DNA marker) in the absence or presence of anti-histone IgG during severe GN crescents. 
Original magnification: x200. (B) Cell viability (MTT assay) was determined by cultured PECs in the 
presence of different serum concentrations together with a low concentration (20μg/ml) of histones 
that without serum reduces PEC viability. (C) PECs viability was measured by MTT assay following 
treatment with anti-TLR2 and anti-TLR4 antibodies and anti-histone IgG to neutralize the histone 
effect on PEC growth. Data are mean OD ± SEM of three experiments measured at a wavelength of 
570 nm. (D) RT-PCR analysis of PECs stimulated with h stones and various neutralizing compounds 
(anti-histone IgG, 50μg/ml heparin, 500nM activated protein C, 1ng/ml anti-TLR2 or -4). Note that all 
these interventions blocked histone-induced CD44 and WT-1 mRNA expression. Data are means ± 
SEM of three experiments. * = P < 0.05, ** = P < 0.01, *** = P < 0.001.  
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Figure: 37. Heparin and activated protein C block histone toxicity on glomerular endothelial cells. 
Glomerular endothelial cells were exposed to increasing doses of histones with or without heparin (A) 
or aPC (B) as indicated and PEC viability determined via MTT assay. Data represent mean OD ± 
SEM of three MTT assay experiments measured at a wavelength of 492 nm. * = P < 0.05, ** = P < 
0.01, *** = P < 0.001. 
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4.6. Delayed onset of histone neutralization still improves severe glomerulonephritis 
The results within this thesis have shown that pre-emptive histone neutralization contributes 
to the amelioration of the pathogenesis of severe GN. This has let us to the question: Could 
histone neutralization be a potential therapeutic approach for treating already established 
severe GN?  
We used the aforementioned three therapeutic interventions including anti-histone IgG, 
heparin, and aPC due to their capability to completely block histone toxicity on glomeruli ex-
vivo (section 4.3.1 and 4.6). To investigate the therapeutic effect of the histone blocking 
agents (anti-histone IgG, heparin and aPC), we stimulated first isolated glomeruli with 
histones at a concentration of 50 µg/ml 24 hour prior to the treatment with agents and 
performed the lactate dehydrogenase (LDH) release as ay to check the cytotoxic effect of 
histone on isolated glomeruli. As shown in Figure 38A, all histone blocking agents 
significantly reduced the LDH release compare to the control IgG or vehicle group.   
To further test the effect of histone neutralization therapeutically, a number of in-vivo 
experiments were performed, whereby 100 µl of GBM antiserum was injected 24 hours prior 
to treatment with anti-histone IgG, heparin, and aPC. On day 2, increased proteinuria and 
elevated BUN levels were observed in all groups independent of the therapeutic intervention 
with histone blocking agents (Figures 38B and 38C). However, on day 7 after establishing 
GN, all treatment approaches significantly reduced plasma creatinine levels, proteinuria, and 
podocyte compared to control IgG (Figures 38B-D). Furthermore, the therapeutic blockade of 
histones not only significantly reduced the percentage of glomeruli with global lesions or 
halted damage (Figure 39A-B) but also the percentags of glomerular crescents by 80% 
(Figure 39C) and the percentage of hpf of cast deposition, which features secondary tubular 
injury (Figure 39D).  
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Figure: 38. Delayed histone blockade still improves glomerulonephritis. (A) Glomeruli were isolated 
from wild type mice and incubated with histones in the presence or absence of anti-histone IgG, 
heparin or aPC. LDH release was measured in the suprnatants as a marker of glomerular cell injury. 
(B) In the model of antiserum-induced GN, anti-histone IgG, heparin or recombinant aPC were 
injected 24 hours following disease onset and the urinary albumin/creatinine ratio was determined. 
(C) Plasma creatinine levels determined on day 7 and albuminuria also on day 2. (D) Podocytes were 
quantified as nephrin/WT-1+ cells on renal sections  day 7. Data represent the means ± SEM of 
three experiments. * = P < 0.05, ** = P < 0.01, *** = P < 0.001.   
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Figure: 39. (A) Periodic acid-Shiff staining (B) Glomerular lesions (C) and the percentage of 
crescentic glomeruli (D) and hpf as tubular injury score measured on day 7. Data represent the means 
± SEM of three experiments. * = P < 0.05, ** = P < 0.01, *** = P < 0.001.   
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Next, we determined the number of infiltrating neutrophils and macrophages within the 
glomeruli by histology as well as looked at the percentage of immune cells in GN-induced 
mice. As demonstrated in Figure 40A and 40B, less neutrophils and macrophages infiltrated 
the glomeruli following treatment with the histone blocking agent anti-histone IgG, heparin 
or aPC. Flow cytometry analysis of kidneys from anti-histone IgG, heparin or aPC-treated 
GN mice showed a significant reduction in the percentage of all intrarenal leukocyte 
subpopulations including neutrophils, macrophages, d ndritic and T cells as well as their 
status of activation compared to control IgG-treated mice (Figure 41A and 41B). 
 
 
Figure: 40. Therapeutic histone blockade and renal leukocytes. R nal sections were obtained on day 
7 and stained for neutrophils (A) and Mac2 (macrophages, B). Data represent mean glomerular cell 
counts ± SEM of 5-6 mice in each group.  * = P < 0.05, ** = P < 0.01, *** = P < 0.001 versus control 
IgG or vehicle. 
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Figure: 41. (A and B) Flow cytometry data of various leukocyte subsets from kidneys of anti-histone 
IgG, heparin or aPC treated GN mice. * = P < 0.05, ** = P < 0.01, *** = P < 0.001 versus control 
IgG or vehicle. 
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4.7. Delayed onset of histone neutralization using combination of histone blocking agents 
improves severe glomerulonephritis but had no additive effects 
Finally, we investigated the effect of histone neutralization using a combination therapy of 
the previously used histone blocking agent anti-histone IgG, heparin and aPC in a GBM 
antiserum induced severe GN model. Although combinatio  therapy using all three agents 
resulted in a reduction in the urinary albumin/creatinine ratio and creatinine levels (Figure 42 
upper and lower), it did not further decrease proteinuria and creatinine levels compared to the 
individual treatments. Taken together, therapeutic histone blockade with anti-histone IgG, 
heparin or aPC and in combination protected from renal dysfunction and structural injury 
during severe GN.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure: 42. (A) Effect of different treatments and combination f anti-histone IgG, heparin and aPC 
on proteinurea of anti-GBM induced glomerulonephritis on day 7 and (B) the creatinine levels. * = P 
< 0.05. 
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5.  Discussion 
There have been many studies that have explored the involvement of DAMPs in association 
with GN. This thesis provides further insights into the novel pathomechanisms involved in 
the progression of GN and CKD, in particular the source, release and toxic effects of 
extracellular histones and the beneficial outcomes of blocking released extracellular histones 
using anti-histone IgG and histone neutralizing agents like heparin and aPC during the 
pathogenesis and progression of necrotizing and crescentic GN. 
The foremost questions we wanted to answer by this research are: Do dying glomerular cells 
and NETting neutrophils release extracellular histones? Are they contributing to the 
development of crescentic GN? Dying glomerular cells and NETs formation within the 
glomerulus have been shown to release cellular componants, which act as DAMPs to elicit 
cytotoxic and immunostimulatory effects on glomerula  cells leading to the progression of 
crescentic GN22,25. The data presented in this thesis also confirm that extracellular histones 
released from dying glomerular cells and NETs exhibited cytotoxic and immunostimulatory 
effects causing the development of crescentic GN. Furthermore, neutralizing extracellular 
histones was effective during both treatment approaches, prophylactically and therapeutically 
indicating that histone neutralizing agents have the potential to serve as therapeutics during 
severe GN. 
As mentioned above, NETosis is a regulated form of neutrophil death and was first 
discovered in 2004 in the context of being a neutrophil-specific mechanism required for 
killing of extracellular bacteria63. Reports have shown that NETosis is not only an 
antibacterial host defense mechanism but can also occur during sterile inflammation because 
NETosis can be triggered via pro-inflammatory cytokines such as TNF-α. Our in-vitro studies 
showed that a sublethal dose of TNF-α is sufficient to trigger NETosis-driven injury in 
glomerular endothelial cells, as illustrated in Figure 43B. The ability of NETs to kill 
glomerular endothelial cells was solely dependent on the presence of histones generated 
within the NETs structure. This killing effect of NETs could be reversed by the addition of 
anti-histone IgG antibody (Figure 43C). Interestingly, blocking NETs in-vivo using the PAD 
inhibitor Cl-amide, which blocks the citrulination of histone H3, prevented NETs formation 
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by neutrophils and resulted in the protection of mice from developing GN. This is consistent 
with previous findings in a mouse model of lupus nephritis188. 
 
 
 
Figure: 43. Diagram representing the formation of NETs in-vitro and killing action of NETs when 
neutrophils get activated in the presence of TNF-α. A) Normal endothelial monolayer with 
unstimulated neutrophils. B) Endothelial monolayer co-cultured with NETs forming neutrophils 
following stimulation with TNF-α. C) Endothelial monolayer with TNF-α-activated neutrophils in the 
presence of anti-histone IgG.   
 
NETosis causes the release of many aggressive proteases, oxygen radicals and potentially 
DAMPs into the extracellular space that drive vascular injury in the glomerulus. For example, 
DAMPs can activate TLRs and other pattern recognitio  receptors of the innate immune 
system leading to sterile inflammation. Our data now demonstrate an essential role for 
DAMPs in particular extracellular histones. Extracellular histones have been reported to 
contribute to endothelial dysfunction, organ failure and death during sepsis as a result of 
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microvascular endothelial cell injury in the lung10. Reports have further explored the 
thrombogenic potential of extracellular histones that exert their action via direct activation of 
endothelial cells and platelets91,93,101,113,139,147. Similarly, in experimental infection and sepsis 
models, NETosis is most likely the source of extracellular histones, whereas in mechanical 
trauma, toxic liver injury, cerebral stroke and post-ischemic renal tubular necrosis histones 
are also released from dying tissue cells9,53. 
The data herein show that injection of extracellular histones in-vivo into healthy mice through 
the renal artery clearly triggered the killing action of histones in glomerular cells, which 
resulted in the progression of glomerulosclerosis. This was the case for anti-GBM-induced 
glomerulosclerosis, as illustrated in Figure 30. The mechanisms involved in histone toxicity 
are not entirely understood. However, there is evidence indicating that histones exert their 
killing activity due to their strong basic charge, a TLR-independent form of cytotoxicity90. 
While the basic charge of histones is required within e nucleus to neutralize acidic residues 
of the DNA, the basic charge outside the cell has te capacity to damage the cell membrane90. 
Reports have shown that the polyanion heparin can block this charge effect of histones, 
which may well explain its antagonistic effect on histone toxicity in-vitro and in-vivo. 
However, we and others discovered that histones elicit a so DAMP-like immunostimulatory 
activity by activating TLR2, TLR4, and the NLRP3 inflammasome in dendritic cells and 
possibly other immune cell types9,93,94,98,121. This represents another pathway of how 
extracellular histones trigger sterile inflammation. Because TLR2 and TLR4 (but not NLRP3) 
are known to induce glomerular injury in the heterolog us anti-GBM GN model and are 
expressed inside the glomerulus in human ANCA vasculitis, we further explored the 
association of the histone-TLR2/4 axis22,168,189-191. The data herein show that Tlr2/4-deficient 
glomeruli were protected from histone-induced injury ex-vivo and in-vivo implying that 
histone-related glomerular injury occurs in a TLR2/4-dependent DAMP manner. However, in 
the presence of serum the cytotoxic effect of histones on PECs can be reversed leading 
instead to PEC proliferation, which was entirely TLR2/4 dependent. Although PEC necrosis 
can be followed by excessive PEC recovery leading to PEC hyperplasia and crescent 
formation192, concomitant plasma leakage and histone release provide additional mitogenic 
stimuli during severe GN185 (Figure 44).  
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Figure: 44. Schematic representation of normal glomeruli and sclerotic glomeruli with capillary 
necrosis, hyperproliferation of PECs leading to cres ents and podocytes detachment and death that 
further aggravates to proteinuria. 
 
To explore the potential efficacy of histone blockade during severe GN, we applied three 
different treatment agents of histone inactivation. The experimental therapeutic approaches of 
histone neutralization were based on pre-emptive or post-induced GN using anti-histone IgG. 
Both therapeutic approaches with anti-histone IgG had a protective effect on the GN 
pathogenesis in accordance with reduced glomerular injury, proteinuria, and serum creatinine 
levels. A similar effect on the pathogenesis of GN by blocking histones was observed 
following heparin treatment, which was consistent with previously published findings in GN 
models193. Furthermore, we have also demonstrated that heparin c n inhibit the direct toxic 
effects of histones on glomerular endothelial cells, which is in line with reports investigating 
other cell types57,93,139,140,147. Previously, aPC has been reported to be able to degra e 
extracellular histones10. Like anti-histone IgG and heparin, aPC was equally effective in 
abrogating extracellular histone toxicity in-vitro and severe GN in-vivo. The fact that 
combination therapy of all three agents did not show any additive effect supports the concept 
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that their protective effect on GN occurs via histone neutralization and not via unrelated 
mechanisms. 
The anti-GBM induced severe GN model mimics the human GN conditions. However, the 
main limitations of this study are that the anti-GBM model is an artificial condition to induce 
GN by using antiserum against the collagen present in the GBM membrane and that the 
pathogenesis is short and severe with a high number of heterologous antibodies, which have 
direct killing effect on glomerular cells unlike inhuman GN. The disease severity might 
differ between the dose and batch of the serum used. Further studies are required to confirm 
the histone neutralization in human disease condition o make an effective treatment of 
blocking histones during GN in humans. 
Taken together, NETosis releases histones into the extracellular space where they exert their 
toxic effects on glomerular endothelial cells and podocytes. Extracellular histone-induced 
glomerular injury depends on signaling through both receptors TLR2 and 4. In contrast, 
histone neutralization either by anti-histone IgG, recombinant aPC or heparin abrogates the 
pathogenesis of GBM antiserum-induced severe GN in both the pre-emptive and post-
established model. In summary, extracellular histones represent a novel therapeutic target in 
severe GN. 
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6. Conclusion 
The research presented within this thesis focused on the functional role of extracellular and 
NETs-related histones during the pathogenesis of severe GN and provides new insights into a 
potential anti-histone therapy in targeting histones to prevent severe GN and CKD. 
The findings of the current study have multiple implications that are listed as followed and 
summarized in Figure 43: 
• Extracellular histones released from dying cells and NETs contribute to glomerular 
cells death, mainly in GEnC. 
• Extracellular histones are pro-inflammatory and activ te dendritic cells and 
macrophages to release inflammatory cytokines. 
• Extracellular histones show its toxic effects by activating TLR2/4 receptors. 
• Extracellular histones activate PECs both in-vitro and in-vivo leading to crescent 
formation. 
• Blockade of NETs by using a PAD inhibitor ameliorates all aspects of GBM 
antiserum-induced glomerulosclerosis. 
• Pre-emptive as well as delayed onset of histone neutralization either by anti-histone 
IgG, recombinant aPC or heparin abrogates all aspect  of GBM antiserum-induced 
severe GN. 
Taken together, our research highlights the importance of extracellular histones as crucial 
mediators of severe GN. 
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Figure: 45. Schematic representation of mechanism involved in the pathogenesis of 
glomerulonephritis and involvement of extracellular histones release from dying glomerular cells and 
NETing neutrophils.   
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7. Future Direction 
It has been reported that histones show their cytotoxici y due to the strong positive charge 
present on their surface, but not much information is currently available regarding the 
specific cell death pathways. Future studies could be undertaken to determine the mechanism 
by which histones show their cytotoxicity. It would also be interesting to know whether 
histones exert cytotoxic effect via special regulated necrosis pathways or by simple apoptosis 
of cells. 
Histones have been demonstrated to be involved in the pathogenicity of GN by killing 
endothelial cells and other glomerular cells. It would be interesting to study the effect of 
different cell death inhibitors in the GBM antiserum-induced GN, for example using 
inhibitors for necroptosis, ferroptosis or Cyclophilin D-mediated necrosis. 
GBM antiserum-induced GN resulted in the infiltration of macrophages and blocking of 
histones reduced both infiltrating cells and cytokine production during the disease. Here it 
would be of interest to investigate the role of histone neutralization and differentiation of 
macrophages into an anti-inflammatory M2-like macrophage phenotype or a wound 
healing/fibrotic-like macrophage phenotype and to lo k at the functional role of these 
macrophage phenotypes during GBM antiserum-induced GN. 
In our GBM antiserum-induced GN in-vivo model, we have reported heparin as a therapeutic 
histone neutralizing agent and showed a good protecti n of the disease progression in regards 
to reducing proteinuria, BUN levels and decreasing inflammation. Therefore, it would be of 
great importance to study the effect of heparin in patients who have severe GN to show its 
valuable clinical efficacy.  
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9. Abbreviations 
AKI Acute kidney injury 
 
PAMPs 
Pathogen-associated molecular 
patterns  
ANCA 
Anti-neutrophil cytoplasmic 
antibody 
 
PAS 
Periodic acid Schiff 
staining 
aPC Activated protein C 
 
PECs Parietal Epithelial Cells 
  
 
PRRs pattern recognition receptors  
BUN Blood urea nitrogen 
   
  
 
RAGE 
Receptor for advanced  
glycation end-products  
DAMPs 
Damage-associated molecular 
patterns  
 
RNA Ribonucleic acid 
DCs Dendritic cells 
 
ROS Reactive oxygen species  
DN Diabetic nephropathy  
 
RPGN 
Rapidly-progressive 
glomerulonephritis  
DNAA Deoxyribonucleic acid 
 
  
  
 
SLE Systemic lupus erythematosus  
ELISA 
Enzyme linked immunosorbent 
assay 
 
  
GBM Glomerular basement membrane 
 
TLRs Tool like receptors 
GEnC Glomerular endothelial cells 
 
TNF Tumor necrosis factor  
GN Glomerulonephritis 
   
  
   HMGB1 High mobility group box-1 
   HSP Heat shock proteins 
   
  
   IFN-γ Interferon-gamma 
   IL Interleukins 
   
  
   LRRs leucine-rich repeats  
   
  
   MPO Myeloperoxidase 
   
  
   NET Neutrophils extracellular traps 
   NLR Nod-like receptor  
   
NLRP3 
NOD-like receptor family,  
pyrin domain containing 3) 
   
  
   O.D. Optical density 
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10.  Appendix 
Composition of buffers used 
FACS buffer :  
Sterile DPBS    500 ml  
Na Azide    500 mg (0.1 % )  
BSA     1 g (0.2 %)  
 
10X HBSS (Hank’s Balanced Saline Solution) with Ca,Mg:  
For 1000 ml  
KCl     4 g  
KH
2
PO
4    
0.6 g  
NaCl     80 g  
Na
2
HPO
4
.2H
2
O   0.621 g  
NaHCO
3    
3.5 g  
CaCl
2     
1.4 g (or CaCl
2
.2H
2
O 1.854 g)  
MgCl
2
.6H
2
O   1 g  
MgSO
4
.7H
2
O    1 g  
D-Glucose    10 g  
Dissolve in 900 ml of distilled water and adjust to pH 7.4 with 1N HCl or 1N NaOH. 
Make up the volume with distilled water to 1000 ml. 
 
 
 
10X HBSS (Hank’s Balanced Saline Solution) without Ca, Mg:  
For 1000 ml  
KCl     4 g  
KH2PO4    0.6 g 
NaCl     80 g  
Na
2
HPO
4
.2H
2
O   0.621 g  
Dissolve in 1000 ml and autoclave.  
 
DNAse stock solution (1 mg/ml):  
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DNAse (type III) 15000 U/6 mg (Sigma D5025)  
To prepared 1 mg/ml solution: 
Add 6 ml of 50 % (w/v) Glycerol in 20 mM Tris-HCl (pH 7.5), 1 mM MgCl2. 
Can be kept at – 20 
0
C for several weeks.  
Caution: Solution is stable only for 1 week at 4
0
C.  
 
50 % Glycerol in 20 mM Tris-HCl (pH 7.5), 1 mM MgCl
2
:  
a. 0.48 g of Tris-HCl in 100 ml of distilled water, adjust pH to 7.4 (= 40 mM)  
b. 50 ml of Glycerol 100 % + 50 ml of 40 mM Tris-HCl (20 mM)  
c. Add 100 ul of 1M MgCl
2 
solution.  
 
Collagenase / DNAse solution:  
1 mg/ml Collagenase, 0.1 mg/ml DNAse in 1X HBSS (with Ca, Mg)  
For 10 ml:  
Collagenase (type I) (Sigma C0130)  10 mg  
1 mg/ml DNAse stock solution   1 ml  
HBSS (with Ca, Mg)    9 ml  
To be preheated in 37 
0
C water bath before use.  
Caution: Prepare freshly every time (Stable only for few days)  
 
Collagenase solution:  
1 mg/ml Collagenase in 1X HBSS (with Ca, Mg)  
For 10 ml:  
Collagenase (type I)    10 mg  
HBSS (with Ca, Mg)    10 ml  
To be preheated in 37 
0
C water bath before use.  
Caution: Prepare freshly every time (Stable only for few days)  
 
 
 
EDTA 2 mM: 
EDTA 7.44 mg in 10 ml HBSS (without Ca, Mg) 
To be preheated in 37 0C water bath before use. 
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Citrate buffer 10X: 
110 mM Sodiumcitrate in ddH2O 
with 2N NaOH to pH 6 
 
PBS: 
2.74 M NaCl 
54 mM KCl 
30 mM KH2PO4 
130 mM Na2HPO4 
in ddH2O 
Adjust pH to 7.5 with HCl 
 
 
TBS (10x): 
  Tris        24.23g 
  NaCl       80.06g 
  Conc. HCL around 17.5ml 
 Make up volume to 1000ml (pH 7.6) 
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